Combination therapies for cancer

By combining anti-B7-H4 antibody with PD-1/PD-L1 antagonist, the problem of low efficiency in the treatment of B7-H4-related cancers in the prior art is solved, and effective for B7-H4-expressing solid tumors is achieved. Enhanced treatment and immune response.

CN113166242BActive Publication Date: 2024-11-19FIVE PRIME THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980071763.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-30
Filing Date
2019-10-15
Publication Date
2024-11-19
Estimated Expiration
2039-10-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively bind anti-B7-H4 antibodies with PD-1/PD-L1 antagonists to treat cancer, and there is a lack of optimized dosage regimens and methods of administration.

Method used

Provided a method for using different doses and frequency of administration by administering to a patient an antibody or antigen-binding fragment thereof specifically bound to B7-H4 in combination with a PD-1/PD-L1 antagonist (such as pembrolizumab), using different doses and frequency of administration, Including 0.1 to 20 mg/kg of antibodies or antigen-binding fragments thereof and 200 mg of pembrolizumab, it is administered intravenously for the treatment of solid tumors such as breast, ovarian and endometrial cancers.

Benefits of technology

Effective treatment of solid tumors expressed in B7-H4 was achieved, and the immune response was enhanced through synergistic effects, and anti-tumor activity and patient survival were improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113166242B_ABST
    Figure CN113166242B_ABST
Patent Text Reader

Abstract

The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 in combination with a PD-1 / PD-L1 antagonist such as an anti-PD-1 antibody to a subject in need thereof, such as a cancer patient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to methods of administering an antibody that specifically binds to human B7-H4 in combination with a PD-1 / PD-L1 antagonist such as pembrolizumab to treat diseases such as cancer. Advantageous dosing regimens are provided. Background Art

[0002] B7-H4 (also known as B7x, B7-S1, and VTCN1) is an immunomodulatory molecule with homology to other B7 family members, including PD-L1. It is a type I transmembrane protein composed of IgV and IgC extracellular domains. Although the expression of B7-H4 in healthy tissues is relatively limited at the protein level, B7-H4 is expressed in several solid tumors, such as gynecological cancers of the breast, ovary, and endometrium. The expression of B7-H4 in tumors is often associated with poor prognosis. The receptor for B7-H4 is unknown, but it is believed that the receptor is expressed on T cells. It is believed that B7-H4 directly inhibits T cell activity.

[0003] Given the expression and function of B7-H4, antibodies that specifically bind to B7-H4 are being developed for use in therapies involving modulation of B7-H4 activity, such as for the treatment of cancer.

[0004] PD-1 is a key immune checkpoint receptor expressed by activated T cells and B cells and mediates immunosuppression. PD-1 is a member of the CD28 receptor family, which includes CD28, CTLA-4, ICOS, PD-1, and BTLA. Two cell surface glycoprotein ligands for PD-1, programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2), have been identified that are expressed on antigen presenting cells as well as many human cancers and have been shown to downregulate T cell activation and cytokine secretion when bound to PD-1. Inhibition of the PD-1 / PD-L1 interaction, for example by anti-PD-1 or anti-PD-L1 antibodies, mediates potent antitumor activity.

[0005] Therefore, effective dosing regimens are needed for administering antibodies that bind to B7-H4 and inhibitors of the PD-1 / PD-L1 interaction. Summary of the invention

[0006] Provided herein are methods for administering anti-B7-H4 antibodies and antigen-binding fragments thereof in combination with PD-1 / PD-L1 antagonists using a therapeutically effective dosage regimen. The anti-B7-H4 antibody and antigen-binding fragment thereof may be the 20502 antibody or an antigen-binding fragment thereof; or an antibody or antigen-binding fragment comprising the heavy chain and light chain variable region CDRs of the 20502 antibody; or an antibody or antigen-binding fragment comprising the heavy chain and light chain variable region of the 20502 antibody, including an afucosylated form of any of the foregoing. The PD-1 / PD-L1 antagonist may be an anti-PD-1 antibody, such as pembrolizumab, or an antibody or antigen-binding fragment comprising the heavy chain and light chain variable region CDRs of pembrolizumab; or an antibody or antigen-binding fragment comprising the heavy chain and light chain variable region of pembrolizumab.

[0007] In certain aspects, a method of treating a solid tumor in a human subject comprises administering to the subject (a) about 0.1 to about 20 mg / kg of an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2 and VL CDR3 sequences of the 20502 antibody; and (b) about 200 mg of pembrolizumab. In certain embodiments, (a) and (b) are administered simultaneously or sequentially.

[0008] In certain aspects, a method of treating a solid tumor in a human subject comprises administering to the subject (a) a pharmaceutical composition comprising (i) an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof specifically binds to human B7-H4 and comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2 and VL CDR3 sequences of the 20502 antibody; and (ii) a pharmaceutically acceptable excipient, wherein at least 95% of the antibody or antigen-binding fragment thereof in the composition is afucosylated, and wherein about 0.1 to about 20 mg / kg of the antibody or antigen-binding fragment thereof is administered; and (b) a pharmaceutical composition comprising pembrolizumab, wherein about 200 mg of pembrolizumab is administered. In certain embodiments, (a) and (b) are administered simultaneously or sequentially.

[0009] In some aspects, the CDRs of the antibody or antigen-binding fragment thereof are CDRs defined by Kabat, CDRs defined by Chothia, or CDRs defined by AbM. In some aspects, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and CDR3 sequences comprise the amino acid sequences shown in SEQ ID NOs: 5-10, respectively.

[0010] In some aspects, about 20 mg / kg or 20 mg / kg of anti-B7-H4 antibody or antigen binding fragment thereof is administered to the subject. In some aspects, about 10 mg / kg or 10 mg / kg of anti-B7-H4 antibody or antigen binding fragment thereof is administered to the subject. In some aspects, about 3 mg / kg or 3 mg / kg of anti-B7-H4 antibody or antigen binding fragment thereof is administered to the subject. In some aspects, about 1 mg / kg or 1 mg / kg of anti-B7-H4 antibody or antigen binding fragment thereof is administered to the subject. In some aspects, about 0.3 mg / kg or 0.3 mg / kg of anti-B7-H4 antibody or antigen binding fragment thereof is administered to the subject. In some aspects, about 0.1 mg / kg or 0.1 mg / kg of anti-B7-H4 antibody or antigen binding fragment thereof is administered to the subject.

[0011] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof and / or pembrolizumab is administered approximately once every three weeks.

[0012] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof and / or pembrolizumab is administered intravenously.

[0013] In certain aspects, B7-H4 has been detected in the solid tumor using immunohistochemistry (IHC) prior to administration.

[0014] In some aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof comprises VH and / or VL, the VH comprising the amino acid sequence listed in SEQ ID NO: 11, and the VL comprising the amino acid sequence listed in SEQ ID NO: 12. In some aspects, the anti-B7-H4 antibody or antigen-binding fragment comprises a heavy chain constant region and / or a light chain constant region. In some aspects, the heavy chain constant region is a human immunoglobulin IgG1 heavy chain constant region, and / or the light chain constant region is a human immunoglobulin IgGκ light chain constant region. In some aspects, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region and / or a light chain constant region, the heavy chain constant region comprises the amino acid sequence listed in SEQ ID NO: 25, and the light chain constant region comprises the amino acid sequence listed in SEQ ID NO: 23. In some aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain and / or a light chain, the heavy chain comprises the amino acid sequence listed in SEQ ID NO: 21, and the light chain comprises the amino acid sequence listed in SEQ ID NO: 22.

[0015] In certain aspects, the antibody or antigen-binding fragment thereof is a human antibody or antigen-binding fragment thereof.

[0016] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof is afucosylated.

[0017] In some aspects, the antibody or antigen binding fragment thereof is a full-length antibody. In some aspects, the antibody or antigen binding fragment thereof is an antigen binding fragment. In some aspects, the antigen binding fragment comprises or is Fab, Fab', F(ab')2, single-chain Fv (scFv), disulfide-linked Fv, V-NAR domain, IgNar, intracellular antibody, IgGΔCH2, mini antibody, F(ab')3, tetravalent antibody, trivalent antibody, bivalent antibody, single domain antibody, DVD-Ig, Fcab, mAb 2 , (scFv)2 or scFv-Fc.

[0018] In certain aspects, fucosylation is not detectable in the composition comprising the anti-B7-H4 antibody.

[0019] In certain aspects, the solid tumor expresses B7-H4.

[0020] In certain aspects, the solid tumor is unresectable, locally advanced, or metastatic.

[0021] In some aspects, the solid tumor is selected from the group consisting of: breast cancer, ductal carcinoma, endometrial carcinoma, ovarian cancer, urothelial carcinoma, non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer and bladder cancer. In some aspects, the solid tumor is breast cancer, ovarian cancer, endometrial carcinoma or urothelial carcinoma. In some aspects, the breast cancer is advanced breast cancer. In some aspects, the breast cancer is HER2 negative breast cancer. In some aspects, the breast cancer is triple negative breast cancer. In some aspects, the breast cancer is hormone receptor (HR) positive breast cancer. In some aspects, the non-small cell lung cancer is squamous cell carcinoma. In some aspects, the subject has not received prior therapy using a PD-1 / PD-L1 antagonist.

[0022] In some aspects, the method also includes the number of immune cells in the tumor being monitored. In some aspects, the method also includes the number of natural killer (NK) cells, CD4+ cells and / or CD8+ cells in the tumor being monitored. In some aspects, the method also includes the cytokine levels of the subject being monitored. In some aspects, the method also includes the IL-2, IL-6, IL-10, TNF and / or interferon gamma (IFNγ) levels of the subject being monitored.

[0023] In certain aspects, administration of the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof produces a synergistic effect.

[0024] In certain aspects, a method of treating a solid tumor in a human subject comprises administering to the subject (i) about 20 mg / kg of an anti-B7-H4 antibody that specifically binds to human B7-H4 and comprises a VH having an amino acid sequence of SEQ ID NO: 11 and a VL having an amino acid sequence of SEQ ID NO: 12; and (ii) about 200 mg of an anti-PD-1 antibody that comprises a VH having an amino acid sequence of SEQ ID NO: 32 and a VL having an amino acid sequence of SEQ ID NO: 33, wherein the anti-B7-H4 antibody and the anti-PD-1 antibody are administered intravenously approximately once every three weeks.

[0025] In certain aspects, a method of treating a solid tumor in a human subject comprises administering to the subject (a) a pharmaceutical composition comprising (i) an anti-B7-H4 antibody that specifically binds to human B7-H4 and comprises a VH having an amino acid sequence of SEQ ID NO: 11 and a VL having an amino acid sequence of SEQ ID NO: 12, and (ii) a pharmaceutically acceptable excipient, wherein at least 95% of the anti-B7-H4 antibody in the composition is afucosylated, and wherein about 20 mg / kg of the antibody is administered; and (b) a pharmaceutical composition comprising an anti-PD-1 antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a VH having an amino acid sequence of SEQ ID NO: 32 and a VL having an amino acid sequence of SEQ ID NO: 33; and a pharmaceutically acceptable excipient, wherein about 200 mg of the antibody or antigen-binding fragment thereof is administered, wherein the anti-B7-H4 antibody and the anti-PD-1 antibody are administered intravenously about once every three weeks.

[0026] In certain aspects, the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 22. In certain aspects, the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 31.

[0027] In certain aspects, the solid tumor is breast cancer or ovarian cancer, optionally wherein the breast cancer is triple-negative breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1A , 1B 1C and 1C show the in vivo anti-tumor efficacy of anti-B7-H4 antibody in combination with anti-PD-1 antibody. (See Example 4.)

[0029] Figure 2 The dose-dependent anti-tumor activity of the anti-B7-H4 antibody was shown. (See Example 4.)

[0030] Figure 3 It is shown that anti-B7-H4 antibodies are combined with anti-PD1 antibodies in a synergistic manner, even when the administered dose of anti-B7-H4 antibodies is not effective as a monotherapy. (See Example 4.) DETAILED DESCRIPTION

[0031] Provided herein are methods of administering antibodies (e.g., monoclonal antibodies) and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) in combination with a PD-1 / PD-L1 antagonist (e.g., pembrolizumab). Anti-B7-H4 antibodies and antigen-binding fragments thereof can be administered in combination with a PD-1 / PD-L1 antagonist (e.g., pembrolizumab), for example, to treat a solid tumor in a subject. In a specific embodiment, about 20 mg / kg, about 10 mg / kg, about 3 mg / kg, about 1 mg / kg, about 0.3 mg / kg, or about 0.1 mg / kg of the antibody or antigen-binding fragment thereof is administered to the subject in combination with about 200 mg of pembrolizumab, for example, wherein the administration is about once every three weeks.

[0032] 4.1 Terminology

[0033] As used herein, the term "B7-H4" refers to mammalian B7-H4 polypeptides, including but not limited to native B7-H4 polypeptides and isoforms of B7-H4 polypeptides. "B7-H4" encompasses full-length, unprocessed B7-H4 polypeptides as well as forms of B7-H4 polypeptides produced by intracellular processing. As used herein, the term "human B7-H4" refers to a polypeptide comprising the amino acid sequence of SEQ ID NO: 1. "B7-H4 polynucleotide", "B7-H4 nucleotide" or "B7-H4 nucleic acid" refers to a polynucleotide encoding B7-H4.

[0034] The term "antibody" means an immunoglobulin molecule that recognizes and specifically binds to a target (such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of the foregoing) by at least one antigen recognition site located in the variable region of the immunoglobulin molecule. As used herein, the term "antibody" encompasses complete polyclonal antibodies, complete monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising antibodies, and any other modified immunoglobulin molecules, as long as the antibody exhibits the desired biological activity. The antibody can be any of the following five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or their subclasses (isotypes) (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), which are referred to as α, δ, ε, γ, and μ, respectively, based on the characteristics of their heavy chain constant domains. Different types of immunoglobulins have different and well-known subunit structures and three-dimensional configurations. Antibodies can be naked or conjugated with other molecules (such as toxins, radioisotopes, etc.).

[0035] The term "antibody fragment" refers to a portion of a complete antibody. "Antigen binding fragment", "antigen binding domain" or "antigen binding region" refers to a portion of a complete antibody that binds to an antigen. An antigen binding fragment may contain the antigen recognition site of a complete antibody (e.g., a complementary determining region (CDR) sufficient to specifically bind to an antigen). Examples of antigen binding fragments of antibodies include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments, linear antibodies and single-chain antibodies. Antigen binding fragments of antibodies may be derived from any animal species, such as rodents (e.g., mice, rats or hamsters) and humans, or may be artificially produced.

[0036] The terms "anti-B7-H4 antibody," "B7-H4 antibody," and "antibody that binds to B7-H4" refer to antibodies that are capable of specifically binding to B7-H4 with sufficient affinity so that the antibody can be used as a diagnostic and / or therapeutic agent in targeting B7-H4. As used herein, the terms "specifically binds," "immunospecifically binds," "immunospecifically recognizes," and "specifically recognizes" are analogous terms in the context of an antibody or antigen-binding fragment thereof. These terms indicate that the antibody or antigen-binding fragment thereof binds to an epitope via its antigen-binding domain, and that binding requires a certain complementarity between the antigen-binding domain and the epitope. Thus, an antibody that "specifically binds" to human B7-H4 (SEQ ID NO: 1) may also bind to B7-H4 from other species (e.g., cynomolgus monkey, mouse and / or rat B7-H4) and / or B7-H4 proteins produced by other human alleles, but binds to unrelated, non-B7-H4 proteins (e.g., other B7 protein family members, such as PD-L1) to an extent that is less than about 10% of the binding of the antibody to B7-H4, as measured, for example, by radioimmunoassay (RIA). In a specific embodiment, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to human, cynomolgus monkey, mouse and rat B7-H4.

[0037] A "monoclonal" antibody or antigen-binding fragment thereof refers to a homogeneous population of antibodies or antigen-binding fragments that participate in highly specific binding of a single antigenic determinant or epitope. This is in contrast to polyclonal antibodies, which typically include different antibodies directed against different antigenic determinants. The term "monoclonal antibody" or antigen-binding fragment thereof encompasses complete and full-length monoclonal antibodies as well as antibody fragments (such as Fab, Fab', F(ab')2, Fv), single-chain (scFv) mutants, fusion proteins comprising antibody portions, and any other modified immunoglobulin molecules comprising an antigen recognition site. In addition, a "monoclonal" antibody or antigen-binding fragment thereof refers to such antibodies and antigen-binding fragments thereof prepared in any number of ways, including but not limited to hybridomas, phage selection, recombinant expression, and transgenic animals.

[0038] As used herein, the terms "variable region" or "variable domain" are used interchangeably and are common in the art. A variable region generally refers to a part of an antibody, generally a part of a light chain or a heavy chain, typically about 110 to 120 amino acids or 110 to 125 amino acids at the amino terminal in a mature heavy chain and about 90 to 115 amino acids in a mature light chain, which differ in sequence between antibodies and are used for the binding and specificity of a specific antibody to its specific antigen. The variability of the sequence is concentrated in those regions referred to as complementary determining regions (CDRs), while the regions with higher conservatism in the variable domains are referred to as framework regions (FRs). It is not desirable to be bound by any particular mechanism or theory, and it is believed that the CDRs of light and heavy chains are primarily responsible for the interaction and specificity of antibodies with antigens. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and human framework regions (FRs). In specific embodiments, the variable region is a primate (e.g., non-human primate) variable region. In certain embodiments, the variable regions comprise rodent or murine CDRs and primate (eg, non-human primate) framework regions (FRs).

[0039] The terms "VL" and "VL domain" are used interchangeably to refer to the light chain variable region of an antibody.

[0040] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody.

[0041] The term "Kabat numbering" and similar terms are well-known in the art, and refer to a system in which the amino acid residues in the heavy chain and light chain variable region of an antibody or its antigen-binding fragment are numbered. In some aspects, CDR can be determined according to the Kabat numbering system (see, for example, Kabat EA and Wu TT (1971) Ann NY Acad Sci 190: 382-391 and Kabat EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Using the Kabat numbering system, the CDR in the antibody heavy chain molecule is usually present in amino acid positions 31 to 35 (which optionally can include one or two additional amino acids (referred to as 35A and 35B in the Kabat numbering scheme) after 35) (CDR1), amino acid positions 50 to 65 (CDR2) and amino acid positions 95 to 102 (CDR3). Using the Kabat numbering system, the CDRs within an antibody light chain molecule are typically present at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3). In a specific embodiment, the CDRs of the antibodies described herein have been determined according to the Kabat numbering scheme.

[0042] In contrast, Chothia refers to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987)). When numbered using the Kabat numbering convention, the ends of the Chothia CDR-H1 loop vary between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insert at H35A and H35B; if both 35A and 35B are absent, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and the Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software.

[0043]

[0044] As used herein, the terms "constant region" and "constant domain" are interchangeable and have their common meaning in the art. The constant region is an antibody portion that is not directly involved in the binding of the antibody to the antigen, but can exhibit a variety of effector functions, such as interactions with Fc receptors, such as the carboxyl terminal portion of the light chain and / or heavy chain. Relative to the immunoglobulin variable domain, the constant region of the immunoglobulin molecule generally has a more conservative amino acid sequence. In some aspects, the antibody or antigen-binding fragment comprises a constant region or portion thereof sufficient for antibody-dependent cell-mediated cytotoxicity (ADCC).

[0045] As used herein, the term "heavy chain" when used with respect to an antibody can refer to any of the different types, e.g., α (α), δ (δ), ε (ε), γ (γ), and μ (μ), based on the amino acid sequence of the constant domain, producing antibodies of the IgA, IgD, IgE, IgG, and IgM categories, respectively, including subclasses of IgG, e.g., IgG1, IgG2, IgG3, and IgG4. Heavy chain amino acid sequences are well known in the art. In a specific embodiment, the heavy chain is a human heavy chain.

[0046] As used herein, the term "light chain" when used with respect to an antibody can refer to any of the different types, such as kappa (κ) or lambda (λ), based on the amino acid sequence of the constant domain. Light chain amino acid sequences are well known in the art. In a specific embodiment, the light chain is a human light chain.

[0047] The term "chimeric" antibody or antigen-binding fragment thereof refers to an antibody or antigen-binding fragment thereof in which the amino acid sequence is derived from two or more species. Typically, the variable regions of the light and heavy chains correspond to the variable regions of an antibody or antigen-binding fragment thereof derived from one mammalian species (e.g., mouse, rat, rabbit, etc.) with the desired specificity, affinity, and capacity, while the constant regions are homologous to sequences in an antibody or antigen-binding fragment thereof derived from another species (usually human) to avoid eliciting an immune response in the species.

[0048] The term "humanized antibody" or its antigen-binding fragment refers to a non-human (e.g., murine) antibody or its antigen-binding fragment form as a specific immunoglobulin chain, chimeric immunoglobulin or its fragment containing minimal non-human (e.g., murine) sequences. Typically, a humanized antibody or its antigen-binding fragment is a human immunoglobulin ("CDR graft") in which residues from a complementary determining region (CDR) are replaced with residues from a CDR of a non-human species (e.g., mouse, rat, rabbit, hamster) with the desired specificity, affinity and ability (Jones et al., Nature 321: 522-525 (1986); Riechmann et al., Nature 332: 323-327 (1988); Verhoeyen et al., Science 239: 1534-1536 (1988)). In some cases, certain Fv framework region (FR) residues of a human immunoglobulin are replaced with corresponding residues from an antibody or fragment of a non-human species with the desired specificity, affinity and ability. Humanized antibodies or their antigen-binding fragments can be further modified by replacing additional residues in the Fv framework region and / or in the non-human CDR residues to improve and optimize the specificity, affinity and / or ability of the antibody or its antigen-binding fragment. In general, a humanized antibody or its antigen-binding fragment will comprise a variable domain containing all or substantially all CDR regions corresponding to non-human immunoglobulins, while all or substantially all FR regions are those of human immunoglobulin consensus sequences. A humanized antibody or its antigen-binding fragment may also comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically at least a portion of a human immunoglobulin. Examples of methods for producing humanized antibodies are described in U.S. Pat. No. 5,225,539; Roguska et al., Proc. Natl. Acad. Sci., USA, 91(3):969-973 (1994); and Roguska et al., Protein Eng. 9(10):895-904 (1996). In some embodiments, a "humanized antibody" is a resurfaced antibody.

[0049] The term "human" antibody or antigen-binding fragment thereof refers to an antibody or antigen-binding fragment thereof having an amino acid sequence derived from a human immunoglobulin locus, wherein such antibody or antigen-binding fragment thereof is prepared using any technique known in the art. This definition of human antibodies or antigen-binding fragments thereof includes complete or full-length antibodies and fragments thereof.

[0050] An "afucosylated" antibody or antigen-binding fragment thereof or an antibody or antigen-binding fragment thereof that "lacks fucose" refers to an IgG1 or IgG3 isotype antibody or antigen-binding fragment thereof that lacks fucose in its constant region glycosylation. Glycosylation of human IgG1 or IgG3 occurs at Asn297, because the core fucosylated biantennary complex oligosaccharide glycosylation terminates at most 2 Gal residues. In some embodiments, the afucosylated antibody lacks fucose at Asn297. Depending on the amount of terminal Gal residues, these structures are named G0, Gl (a 1,6 or a 1,3) or G2 glycan residues. See, e.g., Raju, TS, BioProcess Int. 1: 44-53 (2003). CHO-type glycosylation of antibody Fc is described, e.g., in Routier, F. FL, Glycoconjugate J. 14: 201-207 (1997).

[0051] The method for measuring fucose includes any method known in the art. For the purposes of this article, fucose is detected by the method described in Example 1 of WO2015 / 017600, which is incorporated herein by reference in its entirety. In short, glycan analysis is performed by releasing glycans from antibodies (e.g., by enzymatic release), labeling the glycans with anthranilic acid (2-AA), and then purifying the labeled glycans. Normal phase HPLC with fluorescence detection is used to separate glycans, and the relative content of each glycan in the antibody is measured. Glycans can be clearly identified as lacking or including fucose by mass spectrometry. In some embodiments, fucose is not detectable in a composition comprising a plurality of non-fucosylated antibodies or their antigen-binding fragments. In some embodiments, non-fucosylated antibodies or their antigen-binding fragments have enhanced affinity for FcγRIIIA. In some embodiments, non-fucosylated antibodies or their antigen-binding fragments have enhanced affinity for FcγRIIIA (V158). In some embodiments, the afucosylated antibody or antigen-binding fragment thereof has enhanced affinity for FcγRIIIA (F158).

[0052] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody or antigen-binding fragment thereof) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody or antigen-binding fragment thereof and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by the dissociation constant (K D Affinity can be measured and / or expressed in a variety of ways known in the art, including but not limited to the equilibrium dissociation constant (K D) and equilibrium association constant (K A ). D According to k off / k on The quotient of is calculated, and K A According to k on / k off k on refers to, for example, the association rate constant of an antibody or antigen-binding fragment thereof with an antigen, and k off Refers to, for example, the dissociation of an antibody or its antigen-binding fragment from an antigen. on and k off It can be done by techniques known to those skilled in the art, such as or KinExA to determine.

[0053] As used herein, "epitope" is a term in the art, and refers to a local region of an antigen to which an antibody or its antigen-binding fragment can specifically bind. An epitope can be, for example, a continuous amino acid (linear or continuous epitope) of a polypeptide, or an epitope can be, for example, from two or more non-continuous regions (conformational, non-linear, discontinuous or non-continuous epitopes) of one or more polypeptides. In certain embodiments, the epitope to which an antibody or its antigen-binding fragment specifically binds can be determined by, for example, NMR spectroscopy, X-ray diffraction crystallography, ELISA assay, hydrogen / deuterium exchange in combination with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligopeptide scanning assays and / or mutagenesis mapping (e.g., site-directed mutagenesis mapping). For X-ray crystallography, crystallization can be accomplished using any method known in the art (e.g., Giege R et al., (1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4):339-350; McPherson A (1990) Eur J Biochem 189:1-23; Chayen NE (1997) Structure 5:1269-1274; McPherson A (1976) J Biol Chem 251:6300-6303). Antibody / antigen-binding fragment thereof: Antigen crystals can be studied using well-known X-ray diffraction techniques and can be improved using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; see, e.g., Meth Enzymol (1985) Vols. 114 and 115, edited by Wyckoff HW et al.; US2004 / 0014194) and BUSTER (Bricogne G (1993) Acta Crystallogr D Biol Crystallogr 49 (Pt 1): 37-60; Bricogne G (1997) Meth Enzymol 276A: 361-423, edited by Carter CW; Roversi P et al., (2000) Acta Crystallogr D Biol Crystallogr 56 (Pt 10): 1316-1323). Mutagenesis mapping studies can be performed using any method known to those skilled in the art. For a description of mutagenesis techniques, including alanine scanning mutagenesis, see, for example, Champe M et al., (1995) J Biol Chem 270: 1388-1394 and Cunningham BC & Wells JA (1989) Science 244: 1081-1085.

[0054] The terms "programmed cell death protein 1" and "PD-1" refer to an immunoinhibitory receptor belonging to the CD28 family. PD-1 is primarily expressed on previously activated T cells in vivo and binds to two ligands, PD-L1 and PD-L2. The term "PD-1" as used herein includes human PD-1 (hPD-1), naturally occurring variants and isoforms of hPD-1, and species homologs of hPD-1.

[0055] The terms "programmed cell death 1 ligand 1" and "PD-L1" refer to one of the two cell surface glycoprotein ligands of PD-1 (the other is PD-L2), which downregulate T cell activation and cytokine secretion after binding to PD-1. The term "PD-L1" as used herein includes human PD-L1 (hPD-L1), naturally occurring variants and isoforms of hPD-1, and species homologs of hPD-L1.

[0056] The term "PD-1 / PD-L1 antagonist" refers to a portion that disrupts the PD-1 / PD-L1 signaling pathway. In some embodiments, the antagonist inhibits the PD-1 / PD-L1 signaling pathway by binding to PD-1 and / or PD-L1. In some embodiments, the PD-1 / PD-L1 antagonist also binds to PD-L2. In some embodiments, the PD-1 / PD-L1 antagonist blocks the binding of PD-1 to PD-L1 and optionally to PD-L2. Non-limiting exemplary PD-1 / PD-L1 antagonists include PD-1 antagonists, such as antibodies that bind to PD-1, such as nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA); PD-L1 antagonists, such as antibodies that bind to PD-L1 (e.g., atezolizumab (TECENTRIQ), durvalumab, and avelumab); fusion proteins, such as AMP-224; and peptides, such as AUR-012.

[0057] "Pembrolizumab" refers to a humanized anti-PD-1 monoclonal antibody sold by Merck & Co. The active ingredient of commercial pharmaceutical preparations.

[0058] "Isolated" polypeptides, antibodies, polynucleotides, vectors, cells or compositions are polypeptides, antibodies, polynucleotides, vectors, cells or compositions that are in a form that does not exist in nature. Isolated polypeptides, antibodies, polynucleotides, vectors, cells or compositions include those that have been purified to the extent that they are no longer in the form in which they are found in nature. In some embodiments, the isolated antibodies, polynucleotides, vectors, cells or compositions are substantially pure. As used herein, "substantially pure" refers to at least 50% pure (i.e., free of contaminants), at least 90% pure, at least 95% pure, at least 98% pure or at least 99% pure material.

[0059] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to amino acid polymers of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. The term also encompasses amino acid polymers that have been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of amino acids (including, for example, non-natural amino acids, etc.), as well as other modifications known in the art. It should be understood that because the polypeptides of the present invention are based on antibodies, in certain embodiments, the polypeptides may exist as single chains or associated chains.

[0060] As used herein, the term "host cell" can be any type of cell, such as a primary cell, a cell in culture, or a cell from a cell line. In a specific embodiment, the term "host cell" refers to a cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. The progeny of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule, for example due to mutations or environmental influences that may occur during passage or integration of the nucleic acid molecule into the host cell genome.

[0061] The term "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredient to be effective and that contains no other components that are unacceptably toxic to a subject to which the formulation would be administered. The formulation may be sterile.

[0062] As used herein, the terms "administer," "administering," "administration," and the like refer to methods (e.g., intravenous administration) that can be used to achieve delivery of an agent, such as an anti-B7-H4 antibody or antigen-binding fragment thereof, to a desired site of biological action. Administration techniques that can be used with the agents and methods described herein are found, for example, in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition, Pergamon; and Remington's, Pharmaceutical Sciences, current edition, Mack Publishing Co., Easton, Pa.

[0063] As used herein, the terms "subject" and "patient" are used interchangeably. The subject can be an animal. In some embodiments, the subject is a mammal, such as a non-human animal (e.g., a cow, pig, horse, cat, dog, rat, mouse, monkey or other primate, etc.). In some embodiments, the subject is a cynomolgus monkey. In some embodiments, the subject is a human.

[0064] The term "therapeutically effective amount" refers to an amount of a drug, such as an anti-B7-H4 antibody or antigen-binding fragment thereof, that is effective in treating a disease or condition in a subject. In the case of cancer, a therapeutically effective amount of a drug can reduce the number of cancer cells; reduce tumor size or burden; inhibit cancer cell infiltration into surrounding organs to some extent; inhibit tumor metastasis to some extent; inhibit tumor growth to some extent; alleviate one or more symptoms associated with cancer to some extent; and / or produce a favorable response, such as an increase in progression-free survival (PFS), disease-free survival (DFS), overall survival (OS), complete response (CR), partial response (PR), or in some cases, stable disease (SD), decreased progressive disease (PD), decreased time to progression (TTP), or any combination thereof. To the extent that the drug can prevent growth and / or kill existing cancer cells, it can be cytostatic and / or cytotoxic.

[0065] Terms such as "treat", "treatment", "treatment", "relieve" and "relieve" refer to therapeutic measures that can cure, slow down, alleviate the symptoms of a pathological disorder or condition and / or prevent its progression. Therefore, those in need of treatment include those who have been diagnosed with or suspected of having the disorder. In certain embodiments, a subject's cancer is successfully "treated" according to the methods of the present invention if the patient shows one or more of the following: a decrease in the number of cancer cells or the complete absence of the disease; a decrease in tumor size; inhibition or absence of cancer cell infiltration into surrounding organs, including, for example, cancer spread to soft tissue and bone; inhibition or absence of tumor metastasis; inhibition or absence of tumor growth; alleviation of one or more symptoms associated with a particular cancer; reduced morbidity and mortality; improved quality of life; reduced tumorigenicity, tumorigenic frequency, or tumorigenic capacity of a tumor; reduced number or frequency of cancer stem cells in a tumor; differentiation of tumorigenic cells into a non-tumorigenic state; increased progression-free survival (PFS), disease-free survival (DFS), overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), reduced progressive disease (PD), reduced time to progression (TTP), or any combination thereof.

[0066] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals in which a cell population is characterized by unregulated cell growth. Examples of cancer include, but are not limited to, gynecological cancers (e.g., breast cancer (including triple-negative breast cancer, hormone receptor (HR) positive breast cancer, ductal carcinoma, ovarian cancer, and endometrial cancer)), non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer (e.g., renal cell carcinoma), and bladder cancer (e.g., urothelial cell carcinoma). A cancer may be a "B7-H4-expressing cancer" or a "B7-H4-expressing cancer" or a "B7-H4-positive cancer". Such terms refer to a cancer comprising cells expressing B7-H4. A cancer may be a solid tumor expressing B7-H4. A cancer may be a primary tumor, or may be an advanced or metastatic cancer.

[0067] A "refractory" cancer is one that progresses even though anti-tumor therapy, such as chemotherapy, has been administered to the cancer patient.

[0068] "Recurrent" cancer is cancer that has grown back in the original site or at a distant site after responding to initial therapy.

[0069] As demonstrated herein, administration of an anti-B7-H4 antibody or antigen-binding fragment thereof and an anti-PD-1 antibody or antigen-binding fragment thereof can provide a "synergistic effect" or is "synergistic," i.e., the effect of the active ingredients when used together is greater than the sum of the effects produced by the active ingredients when used alone. A synergistic effect can be obtained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined unit dosage formulation; (2) delivered sequentially, alternatingly, or concurrently as separate formulations; or (3) by some other regimen. In the case of delivery in alternation therapy, a synergistic effect can be obtained when the compounds are administered or delivered sequentially (e.g., by separate injections in separate syringes).

[0070] As used in the disclosure and claims, the singular forms "a," "an," and "the" include plural forms unless the context clearly dictates otherwise.

[0071] It should be understood that when the language "comprising" is used to describe an embodiment herein, other similar embodiments described in terms of "consisting of" and / or "consisting essentially of" are also provided. In the present disclosure, "comprises", "comprising", "containing", and "having", etc. may have the meanings assigned to them by U.S. patent law, and may mean "includes", "including", etc.; "consisting essentially of" or "consists essentially of" also have the meanings assigned to them by U.S. patent law, and the terms are open-ended, allowing existence beyond what is recited, as long as the basic or novel features recited are not changed by existence beyond what is recited, but excluding prior art embodiments.

[0072] Unless expressly fixed or obvious from the context, as used herein, the term "or" is understood to be inclusive. The term "and / or" as used herein in phrases such as "A and / or B" is intended to include "A and B," "A or B," "A," and "B." Likewise, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to cover each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0073] As used herein, the terms "about" and "approximately" when used to modify a numerical value or numerical range mean that a deviation of 5% to 10% above and 5% to 10% below the stated value or range is still within the intended meaning of the stated value or range.

[0074] Any composition or method provided herein can be combined with one or more of any other compositions and methods provided herein.

[0075] 4.2 Methods for treating cancer

[0076] In one aspect, provided herein is a method for treating cancer in a human subject, the method comprising administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition described herein, in combination with (ii) a PD-1 / PD-L1 inhibitor described herein, or a pharmaceutical composition described herein, and wherein (i) and (ii) are administered simultaneously or sequentially. For "simultaneous" administration, in some embodiments, the agents in (i) and (ii) are administered as separate preparations on the same day, one after the other; or in other embodiments, the agents in (i) and (ii) are mixed together before administration and thus administered as a mixture. For example, in some embodiments, the agents in (i) and (ii) can be packaged and stored in the same vial (ie, a fixed dose formulation), or alternatively, the vials containing each individual agent can be mixed together immediately before administration. For "sequential" administration, the agents in (i) and (ii) are administered as separate preparations on different days. In various embodiments, the agent can be administered in vivo by a variety of routes, including but not limited to intravenous routes.

[0077] The combination of an anti-B7-H4 antibody or antigen-binding fragment thereof and a PD-1 / PD-L1 inhibitor may be synergistic.

[0078] In one aspect, the PD-1 inhibitor is pembrolizumab. The following table lists the heavy chain and light chain sequences of pembrolizumab. In the context of the heavy chain and light chain sequences, the CDR sequences are shown in bold, and the variable region sequences are underlined.

[0079] Pembrolizumab sequence

[0080]

[0081] In one aspect, the PD-1 inhibitor is an antibody or antigen-binding fragment comprising the heavy and light chain variable region CDRs of pembrolizumab; or an antibody or antigen-binding fragment comprising the heavy and light chain variable regions of pembrolizumab.

[0082] In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 0.005 to about 20 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially, for example, at a frequency of about once every three weeks.

[0083] In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 0.1 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially, e.g., at a frequency of about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 0.3 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially, e.g., at a frequency of about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 1 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially, e.g., at a frequency of about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 3 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially, e.g., at a frequency of about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 10 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially, for example, at a frequency of about once every three weeks.In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 20 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially, for example, at a frequency of about once every three weeks.

[0084] In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 0.1 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 0.3 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 1 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 3 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 10 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially at a frequency of once every three weeks.In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein, or a pharmaceutical composition thereof described herein, wherein about 20 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered simultaneously or sequentially at a frequency of once every three weeks.

[0085] In certain embodiments of the methods provided herein, the anti-B7-H4 antibody or antigen-binding fragment thereof or the pharmaceutical composition comprising the anti-B7-H4 antibody or antigen-binding fragment thereof is administered intravenously. In certain embodiments of the methods provided herein, pembrolizumab or its pharmaceutical composition is administered intravenously.

[0086] In certain embodiments, provided herein are methods for treating a cancer selected from the group consisting of: breast cancer (e.g., advanced breast cancer, triple-negative breast cancer, hormone receptor (HR) positive breast cancer, or ductal carcinoma), endometrial cancer, ovarian cancer, urothelial carcinoma, non-small cell lung cancer (e.g., squamous cell carcinoma), head and neck squamous cell carcinoma (HNSCC), Hodgkin's lymphoma (e.g., classical Hodgkin's lymphoma), melanoma, pancreatic cancer, thyroid cancer, kidney cancer (e.g., renal cell carcinoma), bladder cancer (e.g., urothelial carcinoma), gastric cancer, cervical cancer, and high microsatellite instability cancer. In a certain embodiment, provided herein are methods for treating advanced breast cancer (including triple-negative breast cancer, hormone receptor (HR) positive), ovarian cancer, endometrial cancer, or urothelial cancer. In a certain embodiment, provided herein are methods for treating breast cancer. In a certain embodiment, the breast cancer is triple-negative breast cancer. In a certain embodiment, provided herein are methods for treating hormone receptor (HR) positive breast cancer. In a certain embodiment, provided herein are methods for treating ovarian cancer. In a certain embodiment, provided herein are methods for treating endometrial cancer. In a certain embodiment, provided herein are methods for treating urothelial cancer. In a certain embodiment, provided herein is a method for treating gastrointestinal cancer. In a certain embodiment, provided herein is a method for treating gynecological cancer. In a certain embodiment, provided herein is a method for treating head and neck cancer. In a certain embodiment, provided herein is a method for treating genitourinary cancer. In a certain embodiment, provided herein is a method for treating genitourinary cancer. In a certain embodiment, provided herein, the subject has not received prior therapy using a PD-1 / PD-L1 antagonist. In certain embodiments, such methods include administering to a patient in need (e.g., a human patient) an anti-B7-H4 antibody or an antigen-binding fragment thereof provided herein, or a pharmaceutical composition comprising an anti-B7-H4 antibody or an antigen-binding fragment thereof provided herein, in combination with a PD-1 / PD-L1 inhibitor or a pharmaceutical composition thereof provided herein.

[0087] In some embodiments, the cancer is a cancer that expresses B7-H4. In certain embodiments, the cancer is a solid tumor that expresses B7-H4. In certain embodiments, B7-H4 has been detected in a biological sample obtained from a subject (e.g., using immunohistochemistry (IHC)).

[0088] The biological sample can be any biological sample obtained from a subject, cell line, tissue, or other cell source that potentially expresses B7-H4. Methods for obtaining tissue biopsies and body fluids from humans are well known in the art. Biological samples include peripheral blood mononuclear cells. The biological sample can also be a blood sample, in which circulating tumor cells (or "CTCs") can express B7-H4 and be detected.

[0089] Determination of the expression level of B7-H4 protein is intended to include qualitatively or quantitatively measuring or estimating the level of B7-H4 protein in a first biological sample, either directly (e.g., by determining or estimating absolute protein levels) or relatively (e.g., by comparing to protein levels in a second biological sample). The level of B7-H4 polypeptide expression in the first biological sample can be measured or estimated and compared to a standard B7-H4 protein level determined from a second biological sample that is not diseased or by averaging levels from a population of samples that are not diseased. As will be appreciated in the art, once a "standard" B7-H4 polypeptide level is known, it can be repeatedly used as a standard for comparison.

[0090] In another embodiment, the anti-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition described herein is administered to a patient (e.g., a human patient) diagnosed with cancer to increase T cells, CD4 + T cells or CD8 +Proliferation of T cells. In such an embodiment, the PD-1 / PD-L1 antagonists described herein, such as pembrolizumab, are administered to patients to block the binding of PD-1 to PD-L1 and PD-L2 and activate T cells. In another embodiment, an anti-B7-H4 antibody or its antigen-binding fragment or pharmaceutical composition is administered to a patient (e.g., a human patient) diagnosed with cancer to increase interferon-γ (IFNγ) production in the patient. In such an embodiment, a PD-1 / PD-L1 antagonist described herein, such as pembrolizumab, is administered to a patient to block the binding of PD-1 to PD-L1 and PD-L2 and activate T cells. In another embodiment, an anti-B7-H4 antibody or its antigen-binding fragment or pharmaceutical composition is administered to a patient (e.g., a human patient) diagnosed with cancer to block the inhibitory activity of B7-H4 against T cells in the patient. In such an embodiment, the PD-1 / PD-L1 antagonists described herein, such as pembrolizumab, are administered to patients to block the binding of PD-1 to PD-L1 and PD-L2 and activate T cells. In another embodiment, an anti-B7-H4 antibody or antigen-binding fragment thereof or a pharmaceutical composition is administered to a patient (e.g., a human patient) diagnosed with cancer to eliminate cancer cells expressing B7-H4 in the patient. In such an embodiment, the PD-1 / PD-L1 antagonists described herein, such as pembrolizumab, are administered to patients to block the binding of PD-1 to PD-L1 and PD-L2 and activate T cells.

[0091] In some embodiments, the present invention relates to an anti-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein, for use in combination with a PD-1 / PD-L1 antagonist such as pembrolizumab or a pharmaceutical composition thereof as a medicament, wherein the medicament is for administering about 0.1 mg / kg to about 20 mg / kg (e.g., about 0.1 mg / kg, about 0.3 mg / kg, about 1 mg / kg, about 3 mg / kg, about 10 mg / kg or about 20 mg / kg) of the antibody or antigen-binding fragment thereof, and about 200 mg of pembrolizumab. In such embodiments, the antibody or antigen-binding fragment thereof and pembrolizumab can be co-formulated or separately formulated for simultaneous or sequential administration. In some aspects, the present invention relates to an anti-B7-H4 antibody or an antigen-binding fragment thereof or a pharmaceutical composition provided herein, for use in a method of treating cancer in combination with a PD-1 / PD-L1 antagonist such as pembrolizumab or a pharmaceutical composition thereof, wherein about 0.1 mg / kg to about 20 mg / kg (e.g., about 0.1 mg / kg, about 0.3 mg / kg, about 1 mg / kg, about 3 mg / kg, about 10 mg / kg or about 20 mg / kg) of the antibody or antigen-binding fragment thereof is administered and about 200 mg of pembrolizumab is administered, wherein the administration is sequential or simultaneous. In some aspects, the present invention relates to an anti-B7-H4 antibody or antigen-binding fragment thereof, or pharmaceutical composition provided herein, for use in a method of treating cancer in a subject in combination with a PD-1 / PD-L1 antagonist such as pembrolizumab, the method comprising administering to the subject about 0.1 mg / kg to about 20 mg / kg (e.g., about 0.1 mg / kg, about 0.3 mg / kg, about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, or about 20 mg / kg) of the antibody or antigen-binding fragment thereof, or pharmaceutical composition provided herein, and administering about 200 mg of pembrolizumab or pharmaceutical composition thereof provided herein, wherein the administration is sequential or simultaneous.

[0092] In some embodiments, the present invention relates to an anti-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein, for use in combination with a PD-1 / PD-L1 antagonist such as pembrolizumab or a pharmaceutical composition thereof as a medicament, wherein the medicament is used to administer 0.1 mg / kg to 20 mg / kg (e.g., 0.1 mg / kg, 0.3 mg / kg, 1 mg / kg, 3 mg / kg, 10 mg / kg or 20 mg / kg) of the antibody or antigen-binding fragment thereof, and 200 mg of pembrolizumab. In such embodiments, the antibody or antigen-binding fragment thereof and pembrolizumab can be co-formulated or separately formulated for simultaneous or sequential administration. In some aspects, the present invention relates to an anti-B7-H4 antibody or an antigen-binding fragment thereof or a pharmaceutical composition provided herein, for use in a method of treating cancer in combination with a PD-1 / PD-L1 antagonist such as pembrolizumab or a pharmaceutical composition thereof, wherein 0.1 mg / kg to 20 mg / kg (e.g., 0.1 mg / kg, 0.3 mg / kg, 1 mg / kg, 3 mg / kg, 10 mg / kg or 20 mg / kg) of the antibody or antigen-binding fragment thereof is administered and 200 mg of pembrolizumab is administered, wherein the administration is sequential or simultaneous. In some aspects, the present invention relates to an anti-B7-H4 antibody or antigen-binding fragment thereof, or pharmaceutical composition provided herein, for use in a method of treating cancer in a subject in combination with a PD-1 / PD-L1 antagonist such as pembrolizumab, the method comprising administering to the subject 0.1 mg / kg to 20 mg / kg (e.g., 0.1 mg / kg, 0.3 mg / kg, 1 mg / kg, 3 mg / kg, 10 mg / kg, or 20 mg / kg) of the antibody or antigen-binding fragment thereof, or pharmaceutical composition provided herein, and administering 200 mg of pembrolizumab or pharmaceutical composition thereof provided herein, wherein the administration is sequential or simultaneous.

[0093] In certain aspects, the amino acids of human PD-1 are:

[0094] MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTE RRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL(SEQ IDNO:40).

[0095] In certain aspects, the amino acid sequence of human PD-L1 is:

[0096] MRIFAVFFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPV TSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET(SEQ IDNO:41).

[0097] 4.3 B7-H4 Antibodies and Antigen-Binding Fragments

[0098] Provided herein are methods for treating cancer in a human subject, comprising administering to the subject an antibody (e.g., a monoclonal antibody, such as a chimeric, humanized or human antibody) and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4), in combination with a PD-1 / PD-L1 antagonist (such as pembrolizumab). Exemplary B7-H4 antibodies and antigen-binding fragments thereof that can be used in the methods provided herein are known in the art. The amino acid sequences of human, cynomolgus monkey, murine and rat B7-H4 are known in the art and are also provided herein, represented by SEQ ID NOs: 1-4, respectively.

[0099] Human B7-H4:

[0100] MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK(SEQ ID NO:1)

[0101] Cynomolgus monkey B7 - H4:

[0102] MASLGQILFWSIISIIFILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVIGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLNSKASLCVSSFLAISWALLPLAPYLMLK(SEQ ID NO:2)

[0103] Mouse B7 - H4

[0104] MASLGQIIFWSIINIIIILAGAIALIIGFGISGKHFITVTTFTSAGNIGEDGTLSCTFEPDIKLNGIVIQWLKEGIKGLVHEFKEGKDDLSQQHEMFRGRTAVFADQVVVGNASLRLKNVQLTDAGTYTCYIRTSKGKGNANL EYKTGAFSMPEINVDYNASSESLRCEAPRWFPQPTVASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTDSEVKRRSQLQLLNSGPSPCVFSSAFVAGWALLSLSCCLMLR(SEQ ID NO:3)

[0105] Rat B7-H4

[0106] MASLGQIIFWSIINVIIILAGAIVLIIGFGISGKHFITVTTFTSAGNIGEDGTLSCTFEPDIKLNGIVIQWLKEGIKGLVHEFKEGKDDLSQQHEMFRGRTAVFADQVVVGNASLRLKNVQLTDAGTYTCYIHTSKGKGNANL EYKTGAFSMPEINVDYNASSESLRCEAPRWFPQPTVASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTDSEVKRRSQLELLNSGPSPCVSSVSAAGWALLSLSCLMLR(SEQ ID NO:4)

[0107] In certain embodiments, the antibodies or antigen-binding fragments thereof used in the methods described herein specifically bind to human B7-H4. In certain embodiments, the antibodies or antigen-binding fragments thereof used in the methods described herein specifically bind to human and cynomolgus monkey B7-H4. In certain embodiments, the antibodies or antigen-binding fragments thereof used in the methods described herein specifically bind to human, murine, and rat B7-H4. In certain embodiments, the antibodies or antigen-binding fragments thereof used in the methods described herein specifically bind to human, cynomolgus monkey, murine, and rat B7-H4.

[0108] B7-H4 contains an IgC extracellular domain (amino acids 153-241 of SEQ ID NO: 1) and an IgV extracellular domain (amino acids 35-146 of SEQ ID NO: 1). In certain embodiments, the antibodies or antigen-binding fragments thereof used in the methods described herein specifically bind to the IgV domain of human B7-H4. Thus, provided herein are methods of administering an antibody or antigen-binding fragment thereof comprising a polypeptide that specifically binds to amino acids 35-146 of SEQ ID NO: 1.

[0109] In certain embodiments, the antibody or antigen-binding fragment thereof used in the methods described herein specifically binds to human B7-H4 and comprises the six CDRs of the 20502 antibody as listed in Tables 1 and 2. "20502" refers to the 20502 antibody described herein.

[0110] Table 1. VH CDR amino acid sequences 1

[0111]

[0112] 1 The VH CDRs in Table 1 are defined according to Kabat.

[0113] Table 2. VL CDR amino acid sequences 2

[0114]

[0115] 2 The VL CDRs in Table 2 were determined according to Kabat.

[0116] In certain embodiments, the antibody or antigen-binding fragment thereof used in the methods described herein specifically binds to human B7-H4 and comprises the VH of the 20502 antibody listed in Table 3.

[0117] Table 3: Variable heavy chain (VH) amino acid sequence

[0118]

[0119] In certain embodiments, the antibody or antigen-binding fragment thereof used in the methods described herein specifically binds to human B7-H4 and comprises the VL of the 20502 antibody listed in Table 4.

[0120] Table 4: Variable light chain (VL) amino acid sequence

[0121]

[0122] In certain embodiments, the antibody or antigen-binding fragment thereof used in the methods described herein specifically binds to human B7-H4 and comprises the VH and VL of the 20502 antibody listed in Tables 3 and 4.

[0123] In certain embodiments, the antibody or antigen-binding fragment thereof used in the methods described herein specifically binds to human B7-H4 and comprises the VH framework region of the 20502 antibody listed in Table 5.

[0124] Table 5. VH FR amino acid sequences 3

[0125]

[0126]

[0127] 3 The VH framework regions described in Table 5 are determined based on the boundaries of the Kabat numbering system of the CDRs. Thus, the VH CDRs are determined by Kabat, and the framework regions are the amino acid residues in the variable region surrounding the CDRs in the format FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0128] In certain embodiments, the antibody or antigen-binding fragment thereof used in the methods described herein specifically binds to human B7-H4 and comprises the VL framework region of the 20502 antibody listed in Table 6.

[0129] Table 6. VL FR amino acid sequence 4

[0130]

[0131] 4 The VL framework regions described in Table 6 are determined based on the boundaries of the Kabat numbering system of the CDRs. Thus, the VL CDRs are determined by Kabat, and the framework regions are the amino acid residues in the variable region surrounding the CDRs in the format FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0132] In certain embodiments, the antibodies or antigen-binding fragments thereof used in the methods described herein specifically bind to human B7-H4 and comprise the four VH framework regions and four VL framework regions of the 20502 antibody listed in Tables 5 and 6.

[0133] In certain embodiments, the antibody or antigen-binding fragment thereof used in the methods described herein specifically binds to human B7-H4 and comprises the heavy chain sequence of the 20502 antibody listed in Table 7.

[0134] Table 7: Full length heavy chain amino acid sequence

[0135]

[0136]

[0137] In certain embodiments, the antibody or antigen-binding fragment thereof used in the methods described herein specifically binds to human B7-H4 and comprises the light chain sequence of the 20502 antibody listed in Table 8.

[0138] Table 8: Full length light chain amino acid sequence

[0139]

[0140] In certain embodiments, the antibody or antigen-binding fragment used in the methods described herein specifically binds to human B7-H4 and comprises the heavy chain sequence and light chain sequence of the 20502 antibody listed in Tables 7 and 8.

[0141] In certain aspects, the antibodies or antigen-binding fragments thereof used in the methods described herein are described by their VL domain alone, or their VH domain alone, or their three VL CDRs alone, or their three VH CDRs alone. See, e.g., Rader C et al., (1998) PNAS 95:8910-8915, which is incorporated herein by reference in its entirety, describing the humanization of mouse anti-αvβ3 antibodies by identifying complementary light or heavy chains from a human light or heavy chain library, respectively, thereby generating humanized antibody variants with an affinity as high as or higher than that of the original antibody. See also Clackson T et al., (1991) Nature 352:624-628, which is incorporated herein by reference in its entirety, describing a method for generating antibodies that specifically bind to a specific antigen by using a specific VL domain (or VH domain) and screening the library for a complementary VH domain or (VL domain). By ELISA, the screening yielded 14 new partners for specific VH domains and 13 new partners for specific VL domains that were strong binders as determined by ELISA. See also Kim SJ and Hong HJ, (2007) J Microbiol 45:572-577, which is incorporated herein by reference in its entirety, describing a method for producing antibodies that specifically bind to a specific antigen by using a specific VH domain and screening a library (e.g., a human VL library) for complementary VL domains; the selected VL domains can then be used to guide the selection of other complementary (e.g., human) VH domains.

[0142] In certain aspects, the CDRs of an antibody or antigen-binding fragment thereof can be identified according to the Chothia numbering scheme, which refers to the positions of immunoglobulin structural loops (see, e.g., Chothia C and Lesk AM, (1987), J Mol Biol 196:901-917; Al-Lazikani B et al., (1997) J Mol Biol 273:927-948; Chothia C et al., (1992) J Mol Biol 227:799-817; Tramontano A et al., (1990) J Mol Biol 215(1):175-82; and U.S. Pat. No. 7,709,226). Generally, when using the Kabat numbering convention, the Chothia CDR-H1 loop occurs at heavy chain amino acids 26 to 32, 33, or 34, the Chothia CDR-H2 loop occurs at heavy chain amino acids 52 to 56, and the Chothia CDR-H3 loop occurs at heavy chain amino acids 95 to 102, while the Chothia CDR-L1 loop occurs at light chain amino acids 24 to 34, the Chothia CDR-L2 loop occurs at light chain amino acids 50 to 56, and the Chothia CDR-L3 loop occurs at light chain amino acids 89 to 97. When numbered using the Kabat numbering convention, the ends of the Chothia CDR-H1 loop vary between H32 and H34, depending on the length of the loop (this is because the Kabat numbering scheme places the insert at H35A and H35B; if both 35A and 35B are absent, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34).

[0143] In certain aspects, provided herein are methods of administering antibodies and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise the Chothia VH and VL CDRs of the 20502 antibody listed in Tables 3 and 4. In certain embodiments, provided herein are methods of administering antibodies or antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise one or more CDRs, wherein the Chothia and Kabat CDRs have the same amino acid sequence. In certain embodiments, provided herein are methods of administering antibodies and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise a combination of Kabat CDRs and Chothia CDRs.

[0144] In certain aspects, the CDRs of an antibody or antigen-binding fragment thereof may be determined according to the IMGT numbering system as described in Lefranc MP, (1999) The Immunologist 7: 132-136 and Lefranc MP et al., (1999) Nucleic Acids Res 27: 209-212. According to the IMGT numbering scheme, VH-CDR1 is located at positions 26 to 35, VH-CDR2 is located at positions 51 to 57, VH-CDR3 is located at positions 93 to 102, VL-CDR1 is located at positions 27 to 32, VL-CDR2 is located at positions 50 to 52, and VL-CDR3 is located at positions 89 to 97. In a specific embodiment, provided herein are methods of administering antibodies and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise the IMGT VH and VL CDRs of the 20502 antibody listed in Tables 3 and 4, e.g., as described in Lefranc MP (1999) supra and Lefranc MP et al., (1999) supra.

[0145] In certain aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to MacCallum RM et al., (1996) J Mol Biol 262:732-745. See also, for example, Martin A. "Protein Sequence and Structure Analysis of Antibody Variable Domains," in Antibody Engineering, Kontermann and Dübel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001). In a specific embodiment, provided herein is a method of administering an antibody or antigen-binding fragment thereof that specifically binds to B7-H4 (e.g., human B7-H4) and comprises the VH and VL CDRs of the 20502 antibody listed in Tables 3 and 4 as determined by the method in MacCallum RM et al.

[0146] In certain aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to the AbM numbering scheme, which refers to the AbM hypervariable regions that represent a compromise between the Kabat CDRs and the Chothia structural loops and is used by Oxford Molecular's AbM antibody modeling software (Oxford Molecular Group, Inc.). In a specific embodiment, provided herein are methods of administering an antibody or antigen-binding fragment thereof that specifically binds to B7-H4 (e.g., human B7-H4) and comprises the VH and VL CDRs of the 20502 antibody listed in Tables 3 and 4 as determined by the AbM numbering scheme.

[0147] In specific aspects, provided herein are methods of administering an antibody comprising a heavy chain and a light chain.

[0148] Regarding the light chain, in a specific embodiment, the light chain of the antibody described herein is a kappa light chain. The constant region of a human kappa light chain may comprise the following amino acid sequence:

[0149] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 23).

[0150] The constant region of the human kappa light chain can be encoded by the following nucleotide sequence:

[0151] CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAG AGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT(SEQ ID NO:24).

[0152] In a specific embodiment, the antibody that immunospecifically binds to a B7-H4 polypeptide (e.g., human B7-H4) for use in the methods described herein comprises a light chain, wherein the amino acid sequence of the VL domain comprises a sequence listed in Table 4, and wherein the constant region of the light chain comprises the amino acid sequence of a human kappa light chain constant region.

[0153] In a specific embodiment, the antibody that immunospecifically binds to B7-H4 (e.g., human B7-H4) for use in the methods described herein comprises a heavy chain, wherein the amino acid sequence of the VH domain comprises the amino acid sequence listed in Table 3, and wherein the constant region of the heavy chain comprises the amino acid sequence of a human gamma (γ) heavy chain constant region.

[0154] The constant region of a human IgG1 heavy chain may comprise the following amino acid sequence:

[0155] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:25).

[0156] The constant region of the human IgG1 heavy chain can be encoded by the following nucleotide sequence:

[0157] GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA。(SEQ ID NO:26).

[0158] In a specific embodiment, the antibody that immunospecifically binds to B7-H4 (e.g., human B7-H4) used in the methods described herein comprises a VH domain and a VL domain, the VH domain and the VL domain comprising the amino acid sequence of any VH and VL domain described herein, and wherein the constant region comprises the amino acid sequence of the constant region of an IgG (e.g., human IgG) immunoglobulin molecule. In another specific embodiment, the antibody that immunospecifically binds to B7-H4 (e.g., human B7-H4) used in the methods described herein comprises a VH domain and a VL domain, the VH domain and the VL domain comprising the amino acid sequence of any VH and VL domain described herein, and wherein the constant region comprises the amino acid sequence of the constant region of an IgG1 (e.g., human IgG1) immunoglobulin molecule.

[0159] It is reported that antibodies with reduced fucose content have increased affinity for Fc receptors, such as FcγRIIIA. Therefore, in certain embodiments, the antibodies or antigen-binding fragments thereof used in the methods described herein have reduced fucose content or lack fucose (i.e., "no fucosylation"). Such antibodies or antigen-binding fragments thereof can be produced using techniques known to those skilled in the art. For example, they can be expressed in cells lacking or lacking fucosylation ability. In a specific example, a cell line with two alleles of the α1,6-fucosyltransferase gene (FUT8) knocked out can be used to produce antibodies or antigen-binding fragments thereof with reduced fucose content. The Lonza system is an example of such a system that can be used to produce antibodies and antigen-binding fragments thereof with reduced fucose content. Alternatively, antibodies or antigen-binding fragments thereof with reduced fucose content or without fucose content can be produced, for example, by: (i) culturing cells under conditions that prevent or reduce fucosylation; (ii) removing fucose post-translationally (e.g., with fucosidase); (iii) adding the desired carbohydrate post-translationally, for example, after recombinant expression of non-glycosylated glycoproteins; or (iv) purifying glycoproteins to select non-fucosylated antibodies or antigen-binding fragments thereof. For methods for producing antibodies with no or reduced fucose content, see, for example, Longmore GD and Schachter H (1982) Carbohydr Res 100: 365-92 and Imai-Nishiya H et al., (2007) BMC Biotechnol. 7: 84.

[0160] In some embodiments, the afucosylated B7-H4 antibody or antigen-binding fragment thereof has enhanced ADCC activity in vitro compared to a fucosylated B7-H4 antibody or antigen-binding fragment thereof having the same amino acid sequence. In some embodiments, the afucosylated B7-H4 antibody or antigen-binding fragment thereof causes specific cleavage that is at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 65, at least 70, or at least 75 percentage points higher than the specific cleavage with the fucosylated B7-H4 antibody. Specific cleavage can be determined as described in Example 2 herein.

[0161] In some embodiments, the B7-H4 antibody or antigen-binding fragment thereof has an enhanced affinity for FcγRIIIA compared to a fucosylated B7-H4 antibody or antigen-binding fragment thereof having the same amino acid sequence. In some embodiments, the non-fucosylated B7-H4 antibody or antigen-binding fragment thereof binds to FcγRIIIA with an affinity at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 7 times, at least 10 times, at least 12 times, at least 15 times, at least 17 times, or at least 20 times higher than the fucosylated B7-H4 antibody or antigen-binding fragment thereof. In some embodiments, the affinity for FcγRIIIA is determined using surface plasmon resonance. In some embodiments, FcγRIIIA is selected from FcγRIIIA (V158) and FcγRIIIA (F158). In some embodiments, FcγRIIIA is FcγRIIIA (V158).

[0162] In some embodiments, the presence of fucose can be determined by methods including high performance liquid chromatography (HPLC), capillary electrophoresis, or MALDI-TOF mass spectrometry.

[0163] In a specific embodiment, the antibody or antigen-binding fragment thereof (i) comprises the CDR sequences of 20502, the VH and VL sequences of 20502, or the heavy and light chain sequences of 20502, and (ii) is afucosylated.

[0164] In a specific embodiment, the composition comprises an antibody or antigen-binding fragment thereof, which (i) comprises a CDR sequence of 20502, a VH and VL sequence of 20502, or a heavy chain and light chain sequence of 20502, and (ii) is afucosylated, for example, wherein at least 95% of the antibodies in the composition are afucosylated, or wherein fucosylation is not detectable in the composition.

[0165] Engineered glycoforms can be used for a variety of purposes, including but not limited to enhancing or reducing effector function. Methods for producing engineered glycoforms in antibodies or antigen-binding fragments thereof described herein include but are not limited to those disclosed in, for example, the following: P et al., (1999) Nat Biotechnol 17:176-180; Davies J et al., (2001) Biotechnol Bioeng 74:288-294; Shields RL et al., (2002) J Biol Chem 277:26733-26740; Shinkawa T et al., (2003) J Biol Chem 278:3466-3473; Niwa R et al., (2004) Clin Cancer Res 1:6248-6255; Presta LG et al., (2002) Biochem Soc Trans 30:487-490; Kanda Y et al., (2007) Glycobiology 17:104-118; U.S. Patent Nos. 6,602,684; 6,946,292; and 7,214,775; U.S. Patent Publication Nos. US 2007 / 0248600; 2007 / 0178551; 2008 / 0060092; and 2006 / 0253928; International Publication Nos. WO 00 / 61739; WO 01 / 292246; WO 02 / 311140; and WO 02 / 30954; Potillegent TM Technology (Biowa, Inc. Princeton, NJ); and Glycosylation engineering technology (Glycartbiotechnology AG, Zurich, Switzerland). See also, for example, Ferrara C et al., (2006) Biotechnol Bioeng 93:851-861; International Publication Nos. WO 07 / 039818; WO 12 / 130831; WO 99 / 054342; WO 03 / 011878; and WO 04 / 065540.

[0166] In certain embodiments, any of the constant region mutations or modifications described herein can be introduced into one or both heavy chain constant regions of an antibody or antigen-binding fragment thereof described herein having two heavy chain constant regions.

[0167] In another specific embodiment, the antibody or antigen-binding fragment thereof described herein that immunospecifically binds to B7-H4 (e.g., human B7-H4) comprises a heavy chain and a light chain, wherein (i) the heavy chain comprises a VH domain comprising the VH CDR1, VL CDR2, and VL CDR3 amino acid sequences of the 20502 antibody listed in Table 1 (SEQ ID NOs: 5, 6, and 7, respectively); (ii) the light chain comprises a VL domain comprising the VLCDR1, VH CDR2, and VH CDR3 amino acid sequences of the 20502 antibody listed in Table 2 (SEQ ID NOs: 8, 9, and 10, respectively); (iii) the heavy chain further comprises a constant heavy chain domain comprising the amino acid sequence of a constant domain of a human IgG1 heavy chain; and (iv) the light chain further comprises a constant light chain domain comprising the amino acid sequence of a constant domain of a human kappa light chain.

[0168] In another specific embodiment, the antibody or antigen-binding fragment thereof described herein that immunospecifically binds to B7-H4 (e.g., human B7-H4) comprises a heavy chain and a light chain, wherein (i) the heavy chain comprises a VH domain comprising the amino acid sequence of the VH domain of the 20502 antibody listed in Table 3 (SEQ ID NO: 11); (ii) the light chain comprises a VL domain comprising the amino acid sequence of the VL domain of the 20502 antibody listed in Table 4 (SEQ ID NO: 12); (iii) the heavy chain further comprises a constant heavy chain domain comprising the amino acid sequence of a constant domain of a human IgG1 heavy chain; and (iv) the light chain further comprises a constant light chain domain comprising the amino acid sequence of a constant domain of a human κ light chain.

[0169] In a specific embodiment, the antibody or antigen binding fragment thereof described herein that immunospecifically binds to B7-H4 (e.g., human B7-H4) exhibits T cell checkpoint blocking activity. In a specific embodiment, the antibody or antigen binding fragment thereof described herein that immunospecifically binds to B7-H4 (e.g., human B7-H4) increases interferon-γ (IFNγ) production in T cells. In a specific embodiment, the antibody or antigen binding fragment thereof described herein that immunospecifically binds to B7-H4 (e.g., human B7-H4) increases T cell proliferation. In a specific embodiment, the antibody or antigen binding fragment thereof described herein that immunospecifically binds to B7-H4 (e.g., human B7-H4) increases CD4+T cell proliferation. In a specific embodiment, the antibody or antigen binding fragment thereof described herein that immunospecifically binds to B7-H4 (e.g., human B7-H4) increases CD8+T cell proliferation.

[0170] In specific embodiments, the antibodies or antigen-binding fragments thereof described herein that immunospecifically bind to B7-H4 (e.g., human B7-H4) exhibit antibody-dependent cellular cytotoxicity (ADCC) activity. In specific embodiments, the antibodies or antigen-binding fragments thereof described herein that immunospecifically bind to B7-H4 (e.g., human B7-H4) exhibit antibody-dependent cellular cytotoxicity (ADCC) activity on a cell line (e.g., SK-BR-3 cells) having at least 300,000 cell surface B7-H4 molecules. In specific embodiments, the antibodies or antigen-binding fragments thereof described herein that immunospecifically bind to B7-H4 (e.g., human B7-H4) exhibit antibody-dependent cellular cytotoxicity (ADCC) activity on a cell line (e.g., HCC1569 cells) having at least 100,000 cell surface B7-H4 molecules. In specific embodiments, the antibodies or antigen-binding fragments thereof described herein that immunospecifically bind to B7-H4 (e.g., human B7-H4) exhibit antibody-dependent cellular toxicity (ADCC) activity on a cell line (e.g., ZR-75-1 cells) having at least 50,000 cell surface B7-H4 molecules. In specific embodiments, the antibodies or antigen-binding fragments thereof described herein that immunospecifically bind to B7-H4 (e.g., human B7-H4) exhibit antibody-dependent cellular toxicity (ADCC) activity on a cell line (e.g., MDA-MB-468 cells) having at least 30,000 cell surface B7-H4 molecules. In specific embodiments, the antibodies or antigen-binding fragments thereof described herein that immunospecifically bind to B7-H4 (e.g., human B7-H4) exhibit antibody-dependent cellular toxicity (ADCC) activity on a cell line (e.g., HCC1964 cells) having at least 15,000 cell surface B7-H4 molecules.

[0171] In a specific aspect, an antigen binding fragment as described herein that immunospecifically binds to B7-H4 (e.g., human B7-H4) is selected from the group consisting of: Fab, Fab', F(ab')2, and scFv, wherein the Fab, Fab', F(ab')2, or scFv comprises a heavy chain variable region sequence and a light chain variable region sequence of an anti-B7-H4 antibody or antigen binding fragment thereof as described herein. Fab, Fab', F(ab')2, or scFv can be produced by any technique known to those skilled in the art. In certain embodiments, Fab, Fab', F(ab')2, or scFv further comprises a portion that extends the half-life of the antibody in vivo. The portion is also referred to as a "half-life extending portion". Any portion known to those skilled in the art for extending the half-life of Fab, Fab', F(ab')2, or scFv in vivo can be used. For example, the half-life extending portion may include an Fc region, a polymer, albumin, or an albumin binding protein or compound. The polymer may include natural or synthetic, optionally substituted linear or branched polyalkylene, polyalkenylene, polyoxyalkylene, polysaccharide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, methoxypolyethylene glycol, lactose, amylose, dextran, glycogen or their derivatives. The substituent may include one or more hydroxyl, methyl or methoxy groups. In certain embodiments, Fab, Fab', F(ab')2 or scFv may be modified by adding one or more C-terminal amino acids for connecting a portion extending the half-life. In certain embodiments, the portion extending the half-life is polyethylene glycol or human serum albumin. In certain embodiments, Fab, Fab', F(ab')2 or scFv is fused to the Fc region.

[0172] 4.4 Pharmaceutical Compositions

[0173] Provided herein are methods of administering a composition comprising an anti-B7-H4 antibody or antigen-binding fragment thereof of the desired purity in a physiologically acceptable carrier, excipient, or stabilizer (Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations used. (See, e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th Edition (2003); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd Edition, Pharmaceutical Press (2000)). The composition to be used for in vivo administration can be sterile. This is easily achieved by, for example, filtration through a sterile filtration membrane.

[0174] In some embodiments, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, for example, wherein at least 80% of the antibodies in the composition are afucosylated. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, for example, wherein at least 85% of the antibodies in the composition are afucosylated. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, for example, wherein at least 90% of the antibodies in the composition are afucosylated. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, for example, wherein at least 95% of the antibodies in the composition are afucosylated. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, e.g., wherein at least 96% of the antibodies in the composition are afucosylated. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, e.g., wherein at least 97% of the antibodies in the composition are afucosylated. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, e.g., wherein at least 98% of the antibodies in the composition are afucosylated. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, e.g., wherein at least 99% of the antibodies in the composition are afucosylated. In a specific embodiment, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises an afucosylated anti-B7-H4 antibody or antigen-binding fragment, wherein fucose is not detectable in the composition.

[0175] In some embodiments, a method of administering a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises (i) an isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, the antibody or antigen-binding fragment thereof comprising (a) heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3, and light chain variable region (VL) CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 5-10, respectively, (b) a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 12, or (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 21 and a light chain comprising the amino acid sequence of SEQ ID NO: 22; and (ii) a pharmaceutically acceptable excipient.

[0176] Also provided herein is a method of administering a pharmaceutical composition, wherein the pharmaceutical composition comprises (i) an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, CDR2 and CDR3 sequences of SEQ ID NOs: 5-10, respectively, and (ii) a pharmaceutically acceptable excipient, wherein at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% of the antibody or antigen-binding fragment thereof in the composition is afucosylated. In one embodiment, (i) the antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 12, or (ii) the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 21 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

[0177] Also provided herein is a method of administering an additional pharmaceutical composition in addition to a pharmaceutical composition comprising an anti-B7-H4 antibody or an antigen-binding fragment thereof. In such an embodiment, the additional pharmaceutical composition comprises a PD-1 / PD-L1 antagonist, such as pembrolizumab. In such an embodiment, the additional pharmaceutical composition comprising pembrolizumab is provided in the form of a 50 mg lyophilized powder in a single-dose vial for reconstitution, or in the form of a solution of 100 mg / 4 ml (25 mg / ml) in a single-dose vial. In such an embodiment, an amount of an additional pharmaceutical composition is provided to deliver 200 mg of pembrolizumab to a patient in a given administration. The additional pharmaceutical composition can be administered simultaneously or sequentially with the pharmaceutical composition comprising an anti-B7-H4 antibody or an antigen-binding fragment thereof.

[0178] 4.5 Antibody Production and Polynucleotides

[0179] Antibodies and antigen-binding fragments thereof that immunospecifically bind to B7-H4 (e.g., human B7-H4) can be produced by any method known in the art for the synthesis of antibodies and antigen-binding fragments thereof, such as by chemical synthesis or by recombinant expression techniques. Unless otherwise indicated, the methods described herein employ conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridization, and related fields within the skill of the art. Such techniques are described, for example, in the references cited herein and are fully described in the literature. See, for example, Sambrook J et al., (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel FM et al., Current Protocols in Molecular Biology, John Wiley & Sons (1987 and annual updates); Current Protocols in Immunology, John Wiley & Sons (1987 and annual updates); annual updates) Gait (editor) (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein (editor) (1991) Oligonucleotides and Analogues: A Practical Approach, IRL Press; Birren B et al., (editor) (1999) Genome Analysis: A Laboratory Manual, Cold Spring Harbor Laboratory Press.

[0180] In certain aspects, provided herein are methods of administering an anti-B7-H4 antibody or antigen-binding fragment thereof, or a pharmaceutical composition comprising such an antibody or fragment, wherein the antibody or fragment is produced by recombinantly expressing a polynucleotide comprising a nucleotide sequence in a host cell.

[0181] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a heavy chain variable region encoded by a polynucleotide comprising a nucleotide sequence shown in Table 9 (i.e., SEQ ID NO: 27). In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a heavy chain variable region encoded by a polynucleotide comprising a nucleotide sequence shown in Table 9 (i.e., SEQ ID NO: 27) and a nucleotide sequence encoding a human gamma (γ) heavy chain constant region. In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a heavy chain variable region encoded by a polynucleotide comprising a nucleotide sequence shown in Table 9 (i.e., SEQ ID NO: 27) and a heavy chain constant domain encoded by a polynucleotide comprising a nucleotide sequence of SEQ ID NO: 26.

[0182] Table 9: Polynucleotide sequences encoding heavy chain variable regions

[0183]

[0184] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a light chain variable region encoded by a polynucleotide comprising a nucleotide sequence shown in Table 10 (i.e., SEQ ID NO: 28). In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a light chain variable region encoded by a polynucleotide comprising a nucleotide sequence shown in Table 10 (i.e., SEQ ID NO: 28) and a nucleotide sequence encoding a human lambda light chain constant region. In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a light chain variable region encoded by a polynucleotide comprising a nucleotide sequence shown in Table 10 (i.e., SEQ ID NO: 28) and a light chain constant domain encoded by a polynucleotide comprising a nucleotide sequence of SEQ ID NO: 24.

[0185] Table 10: Polynucleotide sequences encoding light chain variable regions

[0186]

[0187] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a variable heavy chain encoded by a polynucleotide comprising a nucleotide sequence encoding a variable heavy chain as shown in Table 9 (i.e., SEQ ID NO: 27) and a variable light chain encoded by a polynucleotide comprising a nucleotide sequence encoding a variable light chain as shown in Table 10 (i.e., SEQ ID NO: 28).

[0188] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises (i) a heavy chain encoded by a polynucleotide comprising a nucleotide sequence encoding a variable heavy chain shown in Table 9 (i.e., SEQ ID NO: 27) and a nucleotide sequence encoding a human gamma (γ) heavy chain constant region, and (ii) a light chain encoded by a polynucleotide comprising a nucleotide sequence encoding a variable light chain shown in Table 10 (i.e., SEQ ID NO: 28) and a nucleotide sequence encoding a human lambda light chain constant region.

[0189] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises (i) a heavy chain encoded by a polynucleotide comprising a nucleotide sequence encoding a variable heavy chain as shown in Table 9 (i.e., SEQ ID NO: 27) and a nucleotide sequence encoding a heavy chain constant domain of SEQ ID NO: 26, and (ii) a light chain encoded by a polynucleotide comprising a nucleotide sequence encoding a variable light chain as shown in Table 10 (i.e., SEQ ID NO: 28) and a nucleotide sequence encoding a light chain constant domain of SEQ ID NO: 24.

[0190] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein is encoded by an optimized polynucleotide encoding the anti-B7-H4 antibody or antigen-binding fragment thereof or its domain, which is optimized, for example, by codon / RNA optimization, replacement with a heterologous signal sequence, and elimination of mRNA instability elements. Methods for generating optimized nucleic acids encoding anti-B7-H4 antibodies or antigen-binding fragments thereof or their domains (e.g., heavy chains, light chains, VH domains, or VL domains) for recombinant expression by introducing codon changes (e.g., codon changes that encode the same amino acid due to the degeneracy of the genetic code) and / or eliminating inhibitory regions in mRNA can therefore be performed by employing, for example, the optimization methods described in U.S. Pat. Nos. 5,965,726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498.

[0191] Polynucleotides can be, for example, in RNA form or DNA form. DNA includes cDNA, genomic DNA and synthetic DNA. DNA can be double-stranded or single-stranded. If it is single-stranded, the DNA can be a coding strand or a non-coding (antisense) strand. In certain embodiments, the polynucleotide is a cDNA or DNA lacking one or more introns. In certain embodiments, the polynucleotide is a non-naturally occurring polynucleotide. In certain embodiments, the polynucleotide is recombinantly produced. In certain embodiments, the polynucleotide is isolated. In certain embodiments, the polynucleotide is substantially pure. In certain embodiments, the polynucleotide is purified from natural components.

[0192] In certain aspects, a vector (e.g., an expression vector) comprises a nucleotide sequence encoding an anti-B7-H4 antibody, antigen-binding fragment thereof, or domain thereof for recombinant expression in a host cell, preferably a mammalian cell. In certain aspects, a cell (e.g., a host cell) comprises such a vector for recombinant expression of an anti-B7-H4 antibody, or antigen-binding fragment thereof (e.g., a human or humanized antibody, or antigen-binding fragment thereof) described herein. Thus, a method for producing an antibody, or antigen-binding fragment thereof, described herein may comprise expressing such an antibody, or antigen-binding fragment thereof, in a host cell.

[0193] The expression vector can be transferred to cells (e.g., host cells) by conventional techniques, and the resulting cells can then be cultured by conventional techniques to produce the antibodies or antigen-binding fragments thereof described herein (e.g., antibodies or antigen-binding fragments comprising the six CDRs, VH, VL, VH and VL, heavy chains, light chains, or heavy chains and light chains of 20502) or domains thereof (e.g., VH, VL, VH and VL, heavy chains, or light chains of 20502).

[0194] In certain embodiments, The anti-B7-H4 antibody or antigen-binding fragment thereof (e.g., an antibody or antigen-binding fragment thereof comprising the CDRs of 20502) administered according to the methods provided herein is produced in CHOK1SV cells.

[0195] In some embodiments, the anti-B7-H4 antibody or antigen-binding fragment thereof (e.g., an antibody or antigen-binding fragment thereof comprising the CDRs of 20502) administered according to the methods provided herein is produced in a host cell lacking a functional α-1,6-fucosyltransferase gene (FUT8) gene. In some embodiments, the host cell is a CHO cell.

[0196] In specific embodiments, the antibodies or antigen-binding fragments thereof administered according to the methods provided herein are isolated or purified. Typically, an isolated antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment thereof that is substantially free of other antibodies or antigen-binding fragments thereof that have a different antigenic specificity than the isolated antibody or antigen-binding fragment thereof. For example, in a specific embodiment, the preparations of the antibodies or antigen-binding fragments thereof described herein are substantially free of cellular material and / or chemical precursors.

[0197] The following examples are offered by way of illustration and not by way of limitation.

[0198] 5. Examples

[0199] The examples in this section are offered by way of illustration and not by way of limitation.

[0200] 5.1 Example 1: Assessment of the prevalence of B7-H4 expression in multiple indications

[0201] B7-H4 mouse monoclonal antibody A57.1 (ATCC catalog number PTA-5180) was used to detect the presence of B7-H4 on archival samples, mixtures of whole sections, and tumor microarrays. Samples were treated with primary antibodies and detected using a polymer detection system attached to DAB (Ventana Medical Systems).

[0202] B7-H4 was easily detected in the cell membrane and cytosol of tumor tissues harvested from various cancer patients, including invasive ductal carcinoma, triple-negative breast cancer, ovarian cancer, non-small cell lung cancer, and endometrial cancer. In addition, the expression frequency was also high in the indications listed in Table 11.

[0203] Table 11: B7-H4 detection in tumors

[0204]

[0205] B7-H4 is expressed in other cancers, such as breast cancer, kidney cancer (e.g., renal cell carcinoma), bladder cancer (e.g., urothelial cell carcinoma), pancreatic cancer, and thyroid cancer. See, e.g., Zhu, J., et al., Asian Pacific J. Cancer Prev. 14:3011-3015 (2011); Krambeck A, et al., PNAS 103:10391-10396 (2006); Fan, M. et al., Int. J. Clin. Exp. Pathol. 7:6768-6775 (2014); Xu, H., et al., Oncology Letters 11:1841-1846 (2016); and Liu, W., et al., Oncology Letters 8:2527-2534 (2014).

[0206] 5.2 Example 2: Afucosylated and Fucosylated 20502 Antibodies

[0207] Compared with fully fucosylated antibodies, antibodies having an Fc region with reduced fucose content in the glycan portion can exhibit higher ADCC activity (Niwa R et al., Clinical Cancer Research 11(6):2327-36 (2005)). The B7-H4 antibody was produced in CHO-x cells (Yamane-Ohnuki N, et al. Biotechnology and Bioengineering 87(5):614-22 (2004)) used to produce normally fucosylated antibodies and in a CHO cell line (CHO-y cells) engineered to produce afucosylated antibody (supra).

[0208] Fucosylated and afucosylated 20502 antibodies were characterized by surface plasmon resonance (SPR). Briefly, anti-human Fab antibodies were immobilized on a carboxyl-derivatized SPR chip surface, and anti-B7-H4 antibodies were captured on the resulting surface at 5ug / ml for 30 seconds. B7-H4 IgV-huIgG1 at various concentrations (0nM, 3.7nM, 11.1nM, 33.3nM, 100nM, and 300nM) was then flowed over the surface and allowed to bind to the anti-B7-H4 antibodies during the association phase, followed by a buffer wash during the dissociation phase.

[0209] B7-H4 IgV-huIgG1:

[0210] MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSGSEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:29)

[0211] The data were fitted using a 1:1 binding model, and fucosylated and afucosylated 20502 showed similar binding to human B7-H4 protein. Therefore, glycosylation has no effect on binding.

[0212] The binding affinity of the Fc region of fucosylated 20502 (Ab-F) and non-fucosylated 20502 (Ab-A) to FcγRIIIa (V158) was also characterized by surface plasmon resonance (SPR). In brief, protein A was covalently linked to a dextran chip with 100mM ethylenediamine in 100mM sodium borate buffer (pH 8.0) as a blocking reagent using an amine coupling kit. Ab-A or Ab-F was captured in a separate flow cell at 2 densities, and the protein A derivatization flow served as a reference control. FcγRIIIA (V158) was diluted in HBS-P+ running buffer and injected in duplicate at 6 concentrations (0nM, 1.37nM, 12.3nM, 37nM, 111nM, 333nM and 1000nM). The association constant, dissociation constant and affinity for Ab-A binding were calculated using the Biacore T200 evaluation software 1:1 binding model. The affinity constants for Ab-A and Ab-F binding were determined using the Biacore T200 evaluation software steady-state affinity model. The affinity of the afucosylated B7-H4 antibody for Fcγ receptor IIIA (V158) was 140 times that of the same antibody with fucosylated Fc (Ab-F) (Table 12).

[0213] Table 12: Fcγ receptor IIIa (FcγRIIIa) V158 allele binding

[0214] ka(1 / Ms) kd(1 / s) <![CDATA[K D (nM)]]> Ab-A 6.46E+05 9.54E-10 15 Ab-F N / A N / A 210

[0215] The T cell checkpoint blocking activity of fucosylated and afucosylated 20502 antibodies was also characterized. In these experiments, primary human T cells were enriched from PBMCs using the EasySepTM Human T Cell Enrichment Kit according to the manufacturer's instructions. The enriched T cells were cultured at 2x10 5 10 cells / mL were incubated with anti-CD3 / anti-CD28 Dynabeads at a ratio of one bead per cell at 37°C. After six days, the beads were magnetically removed, and the T cells were washed and plated at 1×10 6 1x10 cells / mL and incubated with 10 U / mL IL-2 at 37°C. Four days later, T cells were washed and resuspended in 1x10 6 cells / mL and 2x10 6Artificial antigen presenting cells (aAPC) at a concentration of 10 cells / mL were incubated at 37°C in the presence of titrated doses of B7-H4 antibodies. aAPCs were treated with mitomycin C for one hour at 37°C and then washed extensively before being added to T cell co-cultures. 72 hours after co-culture of T cells, aAPCs, and B7-H4 antibodies, the plates were centrifuged, and the supernatants were harvested and IFNγ production was assessed by ELISA. IFNγ production was plotted against antibody concentration, and EC50 potency was calculated using nonlinear regression curve fitting (GraphPad Prism).

[0216] As measured by an increase in IFNγ production, the B7-H4 antibody showed potent T cell checkpoint blocking activity. In addition, there was no significant difference in potency between the afucosylated and fucosylated antibodies (Table 13).

[0217] Table 13: T cell checkpoint blockade efficacy

[0218]

[0219] In additional experiments, ADCC activity of fucosylated and afucosylated 20502 antibodies was also characterized against target cell lines expressing B7-H4. Specifically, primary human PBMCs were cultured at 1x10 6 Cells / mL were used for cytokine activation. The next day, the cells were washed and incubated with SK-BR-3 target cells labeled with calcein-AM at a 40:1 effector: target ratio. After incubation for 4 hours, target cell lysis was quantitatively measured using a fluorometer. The sample treated with Triton / X served as the maximum lysis control sample, while the sample treated with a separate culture medium served as the background lysis control sample. The specific lysis percentage (%) was calculated as follows: [1-((sample-culture medium control) / (maximum lysis-culture medium control))]x100. The specific lysis percentage (%) was plotted relative to the antibody concentration, and the EC50 efficacy was calculated using nonlinear regression curve fitting (GraphPad Prism).

[0220] The B7-H4 antibody exhibited potent dose-dependent ADCC activity against the endogenous B7-H4 expressing breast cell line SK-BR-3. In addition, the afucosylated antibody exhibited significantly more potent ADCC activity than the fucosylated antibody (Table 14).

[0221] Table 14: ADCC activity

[0222]

[0223] 5.3 Example 3: Correlation between ADCC activity and receptor density

[0224] B7-H4 density was quantified on the surface of SK-BR-3, HCC1569, ZR-75-1, MDA-MB-48, and HCC1964 cells by FACS according to the manufacturer's instructions. 5 Incubate the cells with 15ug / mL B7-H4 antibody on ice for 25 minutes. TM Simply Cellular (QSC) microspheres (pre-coated with increasing concentrations of anti-mouse IgG capture antibody) were also incubated with 15ug / mL B7-H4 antibody on ice for 25 minutes. After incubation, cells and QSC microspheres were pelleted and washed, and samples were acquired on a flow cytometer. Data were analyzed using FlowJo software. The mean fluorescence intensity (MFI) was calculated and entered into A regression correlating the fluorescence channel value of each bead to its pre-assigned Antibody Binding Capacity (ABC) value will be automatically calculated in the spreadsheet. Once the MFI value of the labeled cells is also added to the template, the ABC value will be assigned.

[0225] The ADCC activity of B7-H4 antibodies against target cell lines expressing B7-H4 with different levels of B7-H4 cell surface density was evaluated. 4 SK-BR-3, HCC1569, ZR-75-1, MDA-MB-468, or HCC1964 target cells were incubated with dose-titrated B7-H4 antibodies at 4°C. After 25 minutes, single-use vials of Jurkat-huCD16 reporter cells from Promega were thawed and 7.5x10 4 Cells were added to the target cell / B7-H4 antibody mixture and incubated at 37°C. After 24 hours, samples were allowed to reach room temperature (RT) and incubated with Bio-Glo buffer. Substrate and luminescence were quantified on an EnVision multilabel reader. Data were plotted as luminescence versus antibody concentration and EC50 potency was calculated using nonlinear regression curve fitting (GraphPad Prism).

[0226] B7-H4 antibody ADCC activity depends on B7-H4 cell surface density: as the number of cell surface molecules decreases, the amount of maximal ADCC activity also decreases. In addition, afucosylated antibodies exhibit improved ADCC activity compared to fucosylated antibodies, especially against target cells with lower B7-H4 cell surface density levels (Figure 1).

[0227] 5.4 Example 4: In vivo anti-tumor efficacy in combination with anti-PD-1 antibodies

[0228] Methods: Eight-week-old female BALB / c mice were purchased from Charles River Laboratories (Hollister, CA) and acclimated for up to two weeks prior to the start of the study. The murine breast cancer cell line 4T1 was engineered to express a chimeric protein containing the extracellular domain of murine B7-H4 and the transmembrane domain of murine B7H3. Tumor cells were plated at 0.5 × 10 5 Cells / 50 μl / mouse were implanted in situ into the mammary fat pad of mice. Before inoculation, cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) for no more than three generations. Cells were grown at 37°C in a humidified environment with 5% CO2. After reaching 80-85% confluence, cells were harvested and resuspended in serum-free RPMI 1640 and injected into the mammary fat pad on the ventral side of each mouse.

[0229] The tumor growth of mice was monitored twice a week after cell implantation. The length and width of each tumor were measured using a caliper, and the volume was calculated according to the following formula: tumor volume (mm3) = (width (mm) × length (mm)2) / 2. On the day of treatment start, all tumors were measured, outliers were excluded, and mice were randomly assigned to treatment groups. For anti-B7-H4 treatment, a 20502 mouse substitute named 20502-msIgG2a-F was used, which contained a 20502 variable region fused to fucosylated mouse IgG2a. As a control, mice were administered msIgG2a (anti-HEL). Starting from the 11th day after inoculation, 20502-msIgG2a-F or msIgG2a was administered four times twice a week by intravenous (iv) injection. Starting from the 11th day after inoculation, anti-PD-1 (a modified version of RMP1-14 (Bio X cells) containing an Fc-silencing msIgG2a domain) was administered twice a week by intraperitoneal (ip) injection. Continue to measure tumors at least twice a week until tumor volume exceeds 10% of the animal's body weight or approximately 2000 mm. 3 until.

[0230] Results: Changes in tumor size, changes in mean tumor volume, and survival percentage are shown in Figure 1A , 1B and 1C. Treatment with 20502-msIgG2a-F or anti-PD-1 significantly reduced tumor growth compared with msIgG2a control (p<0.05). Co-administration of 20502-msIgG2a-F and anti-PD-1 significantly enhanced tumor growth inhibition compared with either monotherapy (p<0.05). In addition, the combination therapy resulted in complete tumor regression in 5 of the 12 mice. P values ​​were calculated using one-way ANOVA analysis of calculated tumor volumes on each day of the study, with multiple comparisons between groups.

[0231] In additional experiments, 20502-msIgG2a-F as a monotherapy exhibited dose-dependent antitumor activity at low doses of 1 mg / kg and 3 mg / kg in the engineered 4T1 model ( Figure 2 Combining 20502-msIgG2a-F at doses of 0.3 mg / kg, 3 mg / kg, or 30 mg / kg with anti-PD-1 antibody (5 mg / kg) produced synergistic antitumor activity in the engineered 4T1 model and the similarly engineered B16 (melanoma) model at almost all 20502-msIgG2a-F doses tested ( Figure 3 (The PD-1 antibody was administered three times on the same day with the first three doses of 20502-msIgG2a-F in the 4T1 model, and twice on the same day with the second and fourth doses of 20502-msIgG2a-F in the B16 model.) This synergistic effect was particularly unexpected for the 0.3 mg / kg dose, as 20502-msIgG2a-F alone at this dose had no apparent effect on tumor volume ( Figure 2 ). In addition, the efficacy (survival percentage) observed when 20502-msIgG2a-F was combined with anti-PD1 at a dose of 0.3 mg / kg was surprisingly comparable to or even better than the efficacy observed when combined with anti-PD1 at a dose of 3 mg / kg or 30 mg / kg. Therefore, these results indicate that anti-PD1 and anti-B7-H4 antibodies are synergistically combined at doses where the latter are ineffective as monotherapy, and this has advantages not only in terms of efficacy but also in terms of safety.

[0232] 5.5 Example 5: Nonclinical Pharmacokinetics

[0233] The pharmacokinetics (PK) and toxicokinetics (TK) of afucosylated 20502 were evaluated in mice, rats, and cynomolgus monkeys following weekly and / or repeated intravenous (IV) administration. The PK profile observed was consistent across all studies. In all species, afucosylated 20502 exhibited linear PK and a dose-proportional increase in exposure (area under the serum concentration-time curve [AUC]) with increasing dose. After 4 weekly administrations of 20502 between the first and last doses, weekly exposure (AUC 0-7天) increased approximately 2-fold; however, steady state was not reached. There were no significant gender differences in the serum afucosylated 20502 concentration-time profiles. In cynomolgus monkeys (across 2 different studies), the half-life estimated from recovery animals ranged from approximately 8.8 days to 12 days with dose levels ranging from 1 to 100 mg / kg. The estimated half-life in rats following administration of a single intravenous infusion of 40 mg / kg was approximately 13.2 days. The PK characteristics of afucosylated 20502 in animals support an IV infusion every 3 weeks (Q3W) dosing regimen in humans.

[0234] 5.6 Example 6: Toxicology

[0235] Toxicology studies of afucosylated 20502 were conducted in rats and cynomolgus monkeys. The studies included a preliminary single-dose pharmacokinetic (PK) / tolerance study in rats, a preliminary repeated-dose toxicity study in cynomolgus monkeys, and an Investigational New Drug (IND)-enabled Good Laboratory Practice (GLP) repeated-dose toxicity study in rats and cynomolgus monkeys and a GLP tissue cross-reactivity study using human, rat, and cynomolgus monkey tissues.

[0236] In a single-dose preliminary tolerability study in rats, animals received doses up to 40 mg / kg as a 30-minute intravenous (IV) infusion. Afucosylated 20502 had no effect on clinical observations, body weight, food consumption, clinical pathology (serum chemistry or hematology) assessments, overall observations, organ weights, or histopathology assessments.

[0237] In the preliminary repeated dose toxicology study, cynomolgus monkeys received 4 doses of up to 100 mg / kg of intravenous non-glycosylated 20502 per week as a 30-minute intravenous infusion. All doses were well tolerated by cynomolgus monkeys. There were no unplanned mortalities related to the test article or changes attributed to the administration of fucosylated 20502 during the evaluation of clinical observations, body weights, clinical pathology, necropsy, organ weights, or histopathology parameters.

[0238] In a repeated dose GLP toxicology study, afucosylated 20502 was administered intravenously to rats and cynomolgus monkeys at dose levels of 1, 10, and 100 mg / kg / dose, four times per week. The reversibility of toxicity was assessed during a 6-week recovery period after the final administration. Evaluation parameters included ophthalmological examination, clinical observations, temperature, body weight, food consumption, hematology, coagulation, clinical chemistry, urinalysis, organ weights, macroscopic and microscopic assessments. In the cynomolgus monkey study, an electrocardiogram (ECG) was also evaluated to assess potential cardiac toxicity.

[0239] During evaluation in the GLP rat study, afucosylated 20502 was generally well tolerated and no toxic effects were attributed to afucosylated 20502. The no observed adverse effect level (NOAEL) in Sprague Dawley rats was considered to be 100 mg / kg / dose.

[0240] In the GLP cynomolgus monkey study, afucosylated 20502 was generally well tolerated, and no adverse events (AEs) attributed to afucosylated 20502 were observed in any of the parameters evaluated. During the study, a higher incidence of diarrhea was observed at the end of the dosing period in the higher dose groups. Due to the higher incidence of affected animals with onset at mid- and high doses and late in the dosing period, it may be related to exposure to afucosylated 20502. There were no microscopic changes in the intestines in animals treated with afucosylated 20502, including animals with diarrhea; therefore, this finding was considered non-adverse but may be related to the test article. There was one death in the study. One animal in the mid-dose recovery group was found dead on study day 35, 14 days after the last dose. Clinical observations, macroscopic and microscopic assessments were consistent with the diagnosis of intestinal volvulus. Intestinal volvulus occasionally occurs in cynomolgus monkeys, and this is considered to be a spontaneous symptom of this animal and is not related to the test article. The NOAEL in cynomolgus monkeys is considered to be 100 mg / kg / dose.

[0241] In addition to the in vivo toxicology studies, a GLP-compliant tissue cross-reactivity study was performed to compare the binding of afucosylated 20502 to a panel of 36 tissues from rats, cynomolgus monkeys, and humans. The results showed that the binding pattern of afucosylated 20502 was similar in the 3 species and was restricted to the mammary epithelium.

[0242] Thus, afucosylated 20502 was well tolerated in cynomolgus monkeys and rats. The NOAEL in both species was found to be 100 mg / kg / dose, the highest dose tested when given as 4 weekly intravenous doses.

[0243] 5.7 Example 7: Phase 1a Dose Escalation / Safety Run-in and Phase 1b Dose Expansion Study of Afucosylated 20502 in Combination with Pembrolizumab

[0244] For convenience, the non-fucosylated 20502 is referred to as A-20502 in this example.

[0245] Title: Phase 1a / 1b study of an anti-B7-H4 antibody in combination with pembrolizumab (anti-PD1 antibody) in patients with advanced solid tumors

[0246] Phase 1a goals and endpoints:

[0247]

[0248]

[0249] Phase 1b objectives and endpoints:

[0250]

[0251]

[0252]

[0253] In certain embodiments, pembrolizumab for injection is provided in a single-dose vial in the form of a sterile, preservative-free white to off-white lyophilized powder. Each vial can be reconstituted and diluted for intravenous infusion. Each 2 mL of this reconstituted solution contains 50 mg pembrolizumab and is formulated in L-histidine (3.1 mg), polysorbate 80 (0.4 mg) and sucrose (140 mg). Hydrochloric acid / sodium hydroxide may be included to adjust the pH value to 5.5. By adding 2.3 mL of sterile water for injection (USP), water is injected along the wall of the vial rather than directly on the lyophilized powder to reconstitute the lyophilized powder (the resulting concentration is 25 mg / mL). Slowly rotate the vial (without shaking) for up to 5 minutes to remove bubbles.

[0254] In other embodiments, pembrolizumab can be injected as a 100 mg / 4 mL (25 mg / mL) solution in a single-use vial. The injection is a sterile, preservative-free, transparent to slightly opalescent, colorless to slightly yellowish solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution. Each 1 mL of solution contains 25 mg of pembrolizumab and is formulated in: L-histidine (1.55 mg), polysorbate 80 (0.2 mg), sucrose (70 mg) and water for injection (USP).

[0255] Study Design: This is a Phase 1a / 1b, open-label, multicenter study to evaluate the dosing, safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of A-20502 in combination with pembrolizumab in advanced solid tumors.

[0256] This study included a Phase 1a dose escalation / safety run-in portion (Phase 1a Dose Escalation) and a Phase 1b dose expansion portion (Phase 1b Dose Expansion) for the combination of A-20502 and pembrolizumab.

[0257] Archival tumor tissue (or fresh biopsy tissue if archival tissue is not available) can be prescreened to test B7-H4 (a transmembrane protein of the B7 family, also known as B7S1, B7x, or VTCN1) expression levels by immunohistochemistry (IHC) performed in a central laboratory for patients in phase 1a dose-finding and phase 1b dose-expansion and for biomarker analysis.

[0258] In certain embodiments, archival tumor tissue and / or fresh biopsy tissue is provided as follows:

[0259] Phase 1a dose escalation:

[0260] Provide archival tumor tissue (or fresh biopsy tissue if archival tissue is not available) for retrospective biomarker analysis of the patient.

[0261] Phase 1a dose finding:

[0262] Archival tumor tissue is evaluated for B7-H4 expression levels by IHC testing performed at a central laboratory for prescreening and for biomarker analysis; if archival tissue is not available, fresh biopsy tissue will be used for this testing.

[0263] • Fresh biopsies will be used during screening and workup.

[0264] Phase 1b dose expansion:

[0265] Archival tumor tissue was used to assess B7-H4 expression levels by IHC testing performed in a central laboratory for prescreening and for biomarker analysis; if archival tissue was not available, fresh biopsy tissue was used for this testing.

[0266] • During screening and post-treatment, a subset of patients (eg, at least 10 patients in each 30-patient cohort) will have fresh biopsies used for extended pharmacodynamic analysis.

[0267] Additional details are provided below for each phase of the study in the Phase 1a dose-escalation and Phase 1b dose-expansion portions of this summary.

[0268] Phase 1a Safety Run-in (A-20502 in Combination with Pembrolizumab): At least 3 patients will be enrolled to participate in the maximum tolerated dose (MTD) and / or recommended dose (RD) of A-20502 as monotherapy in combination with 200 mg Pembrolizumab Q3W and evaluated for dose-limiting toxicities (DLT). Additional patients totaling up to 10 patients may be treated with A-20502 and Pembrolizumab at the RD. If necessary, the dose of A-20502 may be reduced according to the taper algorithm described below. The proposed dose levels are:

[0269] 1aC1: A-20502 (RD) + pembrolizumab 200 mg IV Q3W

[0270] 1aC2: A-20502 (10 mg / kg) + pembrolizumab 200 mg IV Q3W

[0271] 1aC3: A-20502 (3 mg / kg) + pembrolizumab 200 mg IV Q3W

[0272] Abbreviations: IV = intravenous; Q3W = every 3 weeks; RD = recommended dose.

[0273] In some embodiments, the RD is 20 mg / kg. In a phase 1a / 1b monotherapy study for patients with advanced solid tumors, A-20502 was well tolerated at doses up to 20 mg / kg with no dose-limiting toxicity. Based on pharmacokinetic studies of patients in phase 1a / 1b monotherapy studies, the A-20502 trough concentration observed at an RD of 20 mg / kg is expected to reach ≥95% receptor saturation for both B7-H4 and FcγIIIa in terms of affinity. A-20502 achieves dose-proportional exposure at doses of ≥0.3 mg / kg, and has a half-life of 1 to 2 weeks. In different tumor types (breast, ovarian, and endometrial), serum concentrations of A-20502 at 20 mg / kg were similar over time, regardless of whether pembrolizumab was used.

[0274] Other dose levels (e.g., 0.1, 0.3, 1, or 20 mg / kg) may be used in combination studies, for example, based on safety, tolerability, objective response, PK, and pharmacodynamics, and estimates of effective exposure inferred from nonclinical data. For example, a lower or intermediate dose of A-20502 based on safety data may be used. The DLT criteria for the combination of A-20502 and pembrolizumab are as follows:

[0275] A DLT during the Phase 1a dose escalation period was defined as any of the following events, regardless of attribution (except those clearly due to the underlying disease or extrinsic causes):

[0276] Any grade 3 or higher non-hematologic toxicity (except grade 3 nausea, vomiting, and diarrhea) occurring within 21 days of treatment

[0277] Grade 3 nausea, vomiting, or diarrhea that persists for >72 hours despite best supportive care during the first 21 days of treatment

[0278] Febrile neutropenia and / or absolute neutrophil count (ANC) < 1.0 × 10 within the first 21 days of treatment 9 / L of documented infection, grade 4 neutropenia lasting more than 7 days, grade 4 thrombocytopenia (<25.0×10 9 / L), or grade 3 thrombocytopenia (<50.0–25.0×10 9 / L) with bleeding

[0279] Aspartate aminotransferase / alanine aminotransferase (AST / ALT) >3× upper limit of normal (ULN) and concurrent total bilirubin >2×ULN are not associated with liver involvement by cancer

[0280] Any level 4 laboratory value, regardless of clinical sequelae

[0281] Other Level 3 laboratory values ​​that are not clinically significant and do not resolve within 72 hours according to the Investigator and Sponsor agreement

[0282] Specific DLT considerations for the combination of A-20502 and pembrolizumab

[0283] Because pembrolizumab is a known immune checkpoint inhibitor and one of the proposed mechanisms of action of A-20502 is immune checkpoint blockade, immune-related adverse events (irAEs) are expected to occur with this combination. An irAE is defined as a clinically significant AE of unknown etiology that is related to study drug exposure and is consistent with an immune-mediated mechanism. Based on this background, the first occurrence of the following irAEs will not be considered a DLT as they are expected to be treatable with immunotherapy:

[0284] Grade 3 tumor flare (defined as localized pain, irritation, or rash at the site of a known or suspected tumor),

[0285] Grade 3 rash

[0286] Grade 3 immune-related adverse events (irAEs) that resolve to Grade 1 or less within 14 days.

[0287] Transient (resolving within 6 hours of onset) grade 3 infusion-related AEs

[0288] A second occurrence of these events (except grade 3 flares) in the same patient or in a different patient will be considered a DLT.

[0289] The DLT assessment interval begins after the infusion begins on the first day of treatment and continues for 21 days. The algorithm outlined in the table below will be applied to dosing decisions. In response to a DLT, the dose of A-20502 can be reduced as needed. The MTD and / or RD of A-20502 in combination with pembrolizumab will be the dose at which ≤1 / 3-6 patients experience a DLT.

[0290] Algorithm for dose-reduction decisions for safety lead-in of A-20502 in combination with pembrolizumab in Phase 1a:

[0291]

[0292] Phase 1b Combination Expansion:

[0293] Phase 1b may consist of a cohort prospectively identified by IHC as having B7-H4 expression. In certain embodiments, there are two cohorts of A-20502 in combination with pembrolizumab in the following selected tumor types:

[0294] Cohort 1bC1: TNBC (A-20502 in combination with pembrolizumab)

[0295] Cohort 1bC2: Ovarian cancer (A-20502 in combination with pembrolizumab)

[0296] In another embodiment, the Phase 1b combination has an initial cohort, and other cohorts such as TNBC can subsequently be enrolled in the Phase 1b trial:

[0297] Cohort 1bC1: Ovarian cancer (A-20502 in combination with pembrolizumab)

[0298] In certain embodiments, up to 3 additional combined queues may be added.

[0299] Based on emerging available clinical and translational data from the study, additional tumor type cohorts (eg, 30 patients or fewer in any single cohort) may be opened during the trial to be treated with A-20502 in combination with pembrolizumab.

[0300] Dosing: In certain embodiments, A-20502 will be administered as a single dose on Day 1 of each 21-day cycle as a 60-minute (±5-minute) IV infusion Q3W. The dose of A-20502 will be based on body weight on Cycle 1 Day 1 (C1D1). After Cycle 1, the A-20502 dose will be recalculated at each infusion visit as long as the patient's body weight has changed by >10% relative to Cycle 1 Day 1.

[0301] Pembrolizumab will be administered at a dose of 200 mg via 30-minute (±5-minute) IV infusion following completion of the IV infusion of A-20502, starting on Day 1 of Cycle 1 and repeated Q3W on Day 1 of each 21-day cycle.

[0302] There is no pre-specified maximum number of doses for the A-20502 plus pembrolizumab combination. Patients may continue to receive both drugs in combination according to their study-assigned cohort / dose until investigator-assessed disease progression or until the patient meets any other protocol-specified withdrawal criteria. If a patient discontinues one of the two drugs, the patient may continue to receive the other drug alone.

[0303] Patients with progressive disease may be treated beyond disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) if the benefit / risk assessment favors continued administration of study treatment (e.g., if the patient continues to experience clinical benefit as assessed by the investigator and tolerates treatment).

[0304] Study Duration: The study duration for individual patients includes screening (up to 28 days), treatment, and end-of-treatment (EOT) follow-up periods, which include visits at approximately 28 (± 7) days and 100 (± 7) days after the last dose. Since all patients are eligible to receive treatment before disease progression, the actual duration of treatment for each individual patient will vary based on the estimated time to progression of their respective tumor type.

[0305] Additionally, patients enrolled in the Phase 1b dose expansion will be followed for up to 2 years of survival (LTFU, including scans and vital status, Q12W).

[0306] Number of Patients: The estimated number of patients planned for this study is as follows, but this number may be adjusted appropriately.

[0307] Phase 1a may enroll 6 to 22 patients or 10 to 22 patients who will receive the combination of A-20502 and pembrolizumab in the safety run-in. An additional one or two cohorts evaluating the combination of A-20502 and pembrolizumab will be enrolled, e.g., 30 patients or fewer.

[0308] Eligibility Criteria:

[0309] Inclusion criteria: Phase 1a inclusion criteria

[0310] Inclusion criteria for recruitment of patients into Phase 1a were as follows:

[0311] 1) Histologically confirmed solid tumors, excluding primary central nervous system (CNS) tumors.

[0312] 2) Unresectable, locally advanced or metastatic disease.

[0313] 3) Be able to understand and sign the Institutional Review Board / Independent Ethics Committee (IRB / IEC)-approved Informed Consent Form (ICF) prior to any study-specific assessments.

[0314] 4) Refractory or intolerant to existing therapies known to provide clinical benefit for the patient's condition.

[0315] 5) All patients must have at least one measurable lesion at baseline according to RECIST v1.1; tumor sites located in previously irradiated areas or areas receiving other locoregional therapy are not considered measurable unless disease progression has been demonstrated.

[0316] 6) Adequate washout period for prior anticancer therapy (i.e., ≥5 half-lives or 4 weeks from the last dose, whichever is shorter).

[0317] 7) Whether archival tumor tissue is available and consent is given to provide archival tumor for retrospective biomarker analysis, or if archival tissue is not available, the patient must undergo a fresh tumor biopsy during screening (biopsy is required for patients in the Phase 1a dose-finding portion).

[0318] 8) Aged ≥ 18 years when signing the ICF.

[0319] 9) Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

[0320] 10) The researchers considered the life expectancy to be at least 3 months.

[0321] 11) Willing and able to comply with all study procedures.

[0322] 12) Previous radiotherapy must have been completed at least 2 weeks before the first dose of study drug.

[0323] 13) Previous radioactive drugs (e.g., strontium, samarium) must have been completed at least 8 weeks before the first dose of study drug.

[0324] 14) Previous surgery requiring general anesthesia must have been completed at least 1 week before the first dose of study drug. Surgery requiring local / epidural anesthesia must have been completed at least 72 hours before the first dose of study drug. Patients must have recovered from any surgery.

[0325] 15) Screening laboratory values ​​must meet the following criteria:

[0326] hematology

[0327] a. Neutrophils ≥ 1200 cells / μL

[0328] b. Platelet count ≥ 75 × 10 3 / μL

[0329] c. Hemoglobin (Hb) ≥ 9.0 g / dL

[0330] kidney:

[0331] Serum creatinine <1.5×ULN or creatinine clearance (CrCl) ≥40 mL / min (using the Cockcroft / Gault formula)

[0332]

[0333]

[0334] liver:

[0335] d. AST and ALT ≤ 3×ULN (AST and ALT < 5×ULN are allowed in patients with liver metastasis)

[0336] e. Bilirubin <1.5×ULN (except for patients with Gilbert's syndrome, in whom total bilirubin must be <3 mg / dL)

[0337] 16) Negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test ≤ 96 hours before treatment on day 1 of cycle 1 (only for women of childbearing potential).

[0338] 17) In sexually active patients (women and men of childbearing potential), willingness to use 2 effective forms of contraception, 1 of which must be a physical barrier method (condom, diaphragm, or cervical / dome cap), until 6 months after the last dose of A-20502. Other effective forms of contraception include:

[0339] Permanent sterilization (hysterectomy and / or bilateral oophorectomy, or bilateral tubal ligation or vasectomy) at least 6 months before screening

[0340] Women of childbearing potential who have been receiving stable oral contraceptive therapy or an intrauterine device or implant for at least 90 days before the study or who have abstained from sexual activity as a lifestyle

[0341] The inclusion criteria for Phase 1b are as follows:

[0342] 18) All inclusion criteria for Phase 1a (except: inclusion criterion #1).

[0343] 19) Positive B7-H4 expression in archival or fresh tumor samples as assessed by an accompanying validated central laboratory IHC assay.

[0344] 20) A history of other malignancies is allowed, provided that it has been definitively treated within the past 2 years and there is no evidence of recurrence (Exceptions: non-melanoma skin cancer, lobular carcinoma in situ, and cervical cancer in situ that have been definitively treated within 2 years are allowed).

[0345] Additional Cohort-Specific Inclusion Criteria for Phase 1b

[0346] Cohort 1bC1 Ovarian Cancer:

[0347] Diagnosis of histologically or cytologically confirmed recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer that is refractory to existing therapies known to provide clinical benefit

[0348] Progressive disease on or after at least two prior lines of therapy, including at least one platinum-containing regimen, or inability to tolerate additional chemotherapy

[0349] No previous treatment with anti-PD1 or PD-L1 directed drugs

[0350] Queue 1bC2 TNBC :

[0351] Histologically or cytologically confirmed metastatic TNBC

[0352] At least two prior lines of systemic chemotherapy, at least one of which was administered in the metastatic setting

[0353] No previous treatment with anti-PD1 or PD-L1 directed drugs

[0354] Eligibility criteria: Exclusion criteria (Phase 1a and 1b)

[0355] Patients who met any of the following criteria were excluded:

[0356] 1) Systemic drugs that suppress immunosuppressive doses, such as steroids or absorbed topical steroids (prednisone at a dose > 10 mg / day or daily equivalent) must be stopped at least 2 weeks before the first dose of study drug. Short-term high-dose steroids, continuous low-dose (prednisone < 10 mg / day), inhaled, intranasal, intraocular, and intraarticular steroid injections are allowed.

[0357] 2) At screening, the New York Heart Association (NYHA) gave a decrease in heart function of >2 grades.

[0358] 3) Uncontrolled or severe heart disease, such as unstable angina

[0359] 4) At screening, QT interval (QTc) corrected for heart rate >450 msec for males or >470 msec for females according to institutional guidelines.

[0360] 5) History of anti-drug antibodies (ADA), severe allergic reactions, anaphylaxis, or other infusion-related reactions to previous biological agents.

[0361] 6) Known hypersensitivity to any component of the investigational product (IP) formulation and / or to pembrolizumab.

[0362] 7) Vaccines within 4 weeks before the first dose of study drug (e.g., human papillomavirus [HPV] vaccine). Inactivated seasonal influenza vaccine may be given to patients without restriction before and during treatment. Influenza vaccines containing live viruses or other clinically specified vaccinations for infectious diseases (i.e., pneumothorax, varicella, etc.) may be permitted, but must be discussed with the Sponsor's Medical Monitor, and a study drug washout period may be required before and after vaccine administration.

[0363] 8) Current unresolved infection or history of chronic, acute, clinically significant infection (viral, bacterial, fungal, or other) that the investigator believes may exclude the patient from exposure to biological agents or may pose a safety risk to the patient.

[0364] 9) Patients with abnormal serum chemistry values ​​that the investigator considers to be clinically significant. This includes patients who present with clinical signs and symptoms related to their abnormal serum chemistry values, as well as patients who are asymptomatic but whose serum chemistry values ​​are considered by the investigator to be clinically significant (e.g., hypokalemia or hyponatremia).

[0365] 10) Any uncontrolled medical illness or psychiatric disorder that the investigator believes will pose a safety risk to the patient or interfere with study participation or the interpretation of individual patient results.

[0366] 11) Pregnancy or breastfeeding.

[0367] 12) Active, known or suspected autoimmune disease requiring treatment in the past 2 years. Patients with type I diabetes, hypothyroidism requiring hormone replacement only, skin disorders not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia), or conditions that are not expected to recur without external triggers are allowed to be enrolled.

[0368] 13) Known history of a positive human immunodeficiency virus (HIV) 1 or 2 test or known acquired immunodeficiency syndrome (AIDS).

[0369] 14) Test positive for hepatitis B virus surface antigen (HBsAg), or detectable hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection.

[0370] 15) Persistent adverse reactions from previous treatment > Grade 1 (excluding Grade 2 alopecia or peripheral neuropathy) based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).

[0371] 16) Symptomatic interstitial lung disease or inflammatory pneumonia.

[0372] 17) Untreated or active CNS or leptomeningeal metastases. Patients are eligible if metastases have been treated and the patient has recovered neurologically to baseline or is neurologically stable (except for residual signs or symptoms related to CNS treatment) for at least 2 weeks prior to the first dose of study drug.

[0373] 18) Evidence of coagulopathy or bleeding diathesis. Patients were allowed to receive stable therapeutic doses of anticoagulants.

[0374] 19) Completed blood or platelet transfusion within 72 hours before the first dose of study drug.

[0375] 20) Any uncontrolled inflammatory gastrointestinal (GI) disease, including Crohn's disease and ulcerative colitis

[0376] Tests and Observations: Safety assessments included vital signs, weight, physical examination, ECOG performance status, laboratory tests (hematology, serum chemistry, and urinalysis), electrocardiogram (ECG), and monitoring for adverse events (AEs) and concomitant medications.

[0377] Archival tumor tissue will be collected and consent for archival tumor (or willingness to undergo a fresh tumor biopsy during screening) will be provided for biomarker analysis to explore the relationship between baseline target levels, tumor immune phenotype, and pharmacodynamic response.

[0378] Pre-treatment and on-treatment tumor tissue was collected from all patients in the Phase 1a dose-finding and a subset of patients in the Phase 1b dose-expansion (up to 15 patients per 30-patient cohort) for extended pharmacodynamic analysis.

[0379] Efficacy assessments may include radiographic imaging every 6 weeks. Responses will be assessed according to RECIST v1.1.

[0380] Statistical methods

[0381] Efficacy analysis

[0382] ORR can be summarized as frequency and percentage at 90% confidence interval (CI) for each dose / cohort. Duration of response (DOR) for patients with complete response (CR) and partial response (PR) can be summarized by number of responders, number and percentage of events / censorings, and Kaplan-Meier estimate of median DOR at 95% CI. Progression-free survival (PFS) of treated patients can be summarized as number and percentage of patients with PFS at each dose / cohort. PFS can also be summarized using the Kaplan-Meier method at 95% CI. ORR, DOR, and PFS can be determined using RECIST v1.1.

[0383] Pharmacokinetic analysis

[0384] Individual and mean (±SD) serum A-20502 concentration-time data may be tabulated and graphed by dose level / cohort. PK parameters may be tabulated and summarized by dose level / cohort, as appropriate and applicable. The effect of immunogenicity on A-20502 exposure may be assessed, tabulated, and summarized by dose level / cohort, as data permit. Individual and mean (±SD) pembrolizumab concentration-time data C max and C 谷 PK parameters, such as accumulation ratio and achievement of steady state, can be tabulated and summarized by dose level / cohort if data are available.

[0385] Immunogenicity analysis

[0386] Baseline ADA-positive subjects are defined as subjects with ADA-positive samples at baseline. ADA-positive subjects are subjects with at least one ADA-positive sample after treatment initiation relative to baseline. The frequency distribution of baseline ADA-positive subjects and ADA-positive subjects after treatment initiation can be summarized separately for A-20502 and pembrolizumab.

[0387] Pharmacodynamic analysis

[0388] Selected pharmacodynamic biomarkers were evaluated for meaningful changes between tumor and peripheral blood samples before and during treatment.

[0389] ***

[0390] The scope of the present invention is not limited by the specific embodiments described herein. In fact, in addition to those described, various modifications to the invention will become apparent to those skilled in the art based on the foregoing description and the accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

[0391] All references (e.g., publications or patents or patent applications) cited herein are incorporated by reference in their entirety and for all purposes to the same extent as if each individual reference (e.g., publication or patent or patent application) was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

[0392] Other implementations are within the following claims. Sequence Listing <110> FIVE PRIME THERAPEUTICS, INC <120> Combination therapies for cancer <130> 3986.018PC03 <150> US 62 / 854,494 <151> 2019-05-30 <150> US 62 / 802,091 <151> 2019-02-06 <150> US 62 / 745,464 <151> 2018-10-15 <160> 41 <170> PatentIn version 3.5 <210> 1 <211> 282 <212> PRT <213> Homo sapiens <400> 1 Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile 1 5 10 15 Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser 20 25 30 Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile 35 40 45 Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu 50 55 60 Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val 65 70 75 80 His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met 85 90 95 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn 100 105 110 Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr 115 120 125 Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu 130 135 140 Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn 145 150 155 160 Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln 165 170 175 Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser 180 185 190 Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met 195 200 205 Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser 210 215 220 Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val 225 230 235 240 Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser 245 250 255 Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu 260 265 270 Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys 275 280 <210> 2 <211> 282 <212> PRT <213> Artificial Sequence <220> <223> Cynomolgus B7-H4 <400> 2 Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile 1 5 10 15 Phe Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser 20 25 30 Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile 35 40 45 Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu 50 55 60 Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Ile Gly Leu Val 65 70 75 80 His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met 85 90 95 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn 100 105 110 Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr 115 120 125 Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu 130 135 140 Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn 145 150 155 160 Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln 165 170 175 Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser 180 185 190 Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met 195 200 205 Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser 210 215 220 Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val 225 230 235 240 Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser 245 250 255 Lys Ala Ser Leu Cys Val Ser Ser Phe Leu Ala Ile Ser Trp Ala Leu 260 265 270 Leu Pro Leu Ala Pro Tyr Leu Met Leu Lys 275 280 <210> 3 <211> 283 <212> PRT <213> Artificial Sequence <220> <223> Murine B7 - H4 <400> 3 Met Ala Ser Leu Gly Gln Ile Ile Phe Trp Ser Ile Ile Asn Ile Ile 1 5 10 15 Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser 20 25 30 Gly Lys His Phe Ile Thr Val Thr Thr Phe Thr Ser Ala Gly Asn Ile 35 40 45 Gly Glu Asp Gly Thr Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu 50 55 60 Asn Gly Ile Val Ile Gln Trp Leu Lys Glu Gly Ile Lys Gly Leu Val 65 70 75 80 His Glu Phe Lys Glu Gly Lys Asp Asp Leu Ser Gln Gln His Glu Met 85 90 95 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Val Val Gly Asn 100 105 110 Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr 115 120 125 Thr Cys Tyr Ile Arg Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu 130 135 140 Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Ile Asn Val Asp Tyr Asn 145 150 155 160 Ala Ser Ser Glu Ser Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln 165 170 175 Pro Thr Val Ala Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser 180 185 190 Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met 195 200 205 Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser 210 215 220 Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val 225 230 235 240 Thr Asp Ser Glu Val Lys Arg Arg Ser Gln Leu Gln Leu Leu Asn Ser 245 250 255 Gly Pro Ser Pro Cys Val Phe Ser Ser Ala Phe Val Ala Gly Trp Ala 260 265 270 Leu Leu Ser Leu Ser Cys Cys Leu Met Leu Arg 275 280 <210> 4 <211> 282 <212> PRT <213> Artificial Sequence <220> <223> Rat B7-H4 <400> 4 Met Ala Ser Leu Gly Gln Ile Ile Phe Trp Ser Ile Ile Asn Val Ile 1 5 10 15 Ile Ile Leu Ala Gly Ala Ile Val Leu Ile Ile Gly Phe Gly Ile Ser 20 25 30 Gly Lys His Phe Ile Thr Val Thr Thr Phe Thr Ser Ala Gly Asn Ile 35 40 45 Gly Glu Asp Gly Thr Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu 50 55 60 Asn Gly Ile Val Ile Gln Trp Leu Lys Glu Gly Ile Lys Gly Leu Val 65 70 75 80 His Glu Phe Lys Glu Gly Lys Asp Asp Leu Ser Gln Gln His Glu Met 85 90 95 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Val Val Gly Asn 100 105 110 Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr 115 120 125 Thr Cys Tyr Ile His Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu 130 135 140 Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Ile Asn Val Asp Tyr Asn 145 150 155 160 Ala Ser Ser Glu Ser Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln 165 170 175 Pro Thr Val Ala Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser 180 185 190 Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met 195 200 205 Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser 210 215 220 Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val 225 230 235 240 Thr Asp Ser Glu Val Lys Arg Arg Ser Gln Leu Glu Leu Leu Asn Ser 245 250 255 Gly Pro Ser Pro Cys Val Ser Ser Val Ser Ala Ala Gly Trp Ala Leu 260 265 270 Leu Ser Leu Ser Cys Cys Leu Met Leu Arg 275 280 <210> 5 <211> 11 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> VH CDR1 <400> 5 Gly Ser Ile Lys Ser Gly Ser Tyr Tyr Trp Gly 1 5 10 <210> 6 <211> 16 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> VH CDR2 <400> 6 Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Arg Ser 1 5 10 15 <210> 7 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> VH CDR3 <400> 7 Ala Arg Glu Gly Ser Tyr Pro Asn Gln Phe Asp Pro 1 5 10 <210> 8 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> VL CDR1 <400> 8 Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala 1 5 10 <210> 9 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> VL CDR2 <400> 9 Gly Ala Ser Thr Arg Ala Thr 1 5 <210> 10 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> VL CDR3 <400> 10 Gln Gln Tyr His Ser Phe Pro Phe Thr 1 5 <210> 11 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> VH Amino Acids <400> 11 Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Lys Ser Gly 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Arg Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Glu Gly Ser Tyr Pro Asn Gln Phe Asp Pro Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 12 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> VL amino acid <400> 12 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Phe Pro Phe 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 13 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> VH FR1 <400> 13 Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly 20 25 <210> 14 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> VH FR2 <400> 14 Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly 1 5 10 <210> 15 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> VH FR3 <400> 15 Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys 1 5 10 15 Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 20 25 30 <210> 16 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> VH FR4 <400> 16 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 1 5 10 <210> 17 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> VL FR1 <400> 17 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys 20 <210> 18 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> VL FR2 <400> 18 Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 1 5 10 15 <210> 19 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> VL FR3 <400> 19 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 1 5 10 15 Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys 20 25 30 <210> 20 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> VL FR4 <400> 20 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 1 5 10 <210> 21 <211> 450 <212> PRT <213> Artificial Sequence <220> <223> Full - length heavy - chain amino acids <400> 21 Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Lys Ser Gly 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Arg Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Glu Gly Ser Tyr Pro Asn Gln Phe Asp Pro Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 22 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Full - length light - chain amino acids <400> 22 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Phe Pro Phe 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 23 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Constant region of human κ light chain <400> 23 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 24 <211> 321 <212> DNA <213> Artificial Sequence <220> <223> Constant region of human κ light chain <400> 24 cggaccgtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct 60 ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag 120 tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac 180 agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240 aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300 agcttcaaca ggggagagtg t 321 <210> 25 <211> 330 <212> PRT <213> Artificial Sequence <220> <223> Human IgG1 heavy chain <400> 25 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 26 <211> 990 <212> DNA <213> Artificial Sequence <220> <223> Heavy chain constant domain <400> 26 gcctccacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg 60 ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120 tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180 ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240 tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc 300 aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga 360 ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420 gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480 tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540 agcacgtacc gggtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600 gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660 aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag 720 ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc 780 gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg 840 ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg 900 cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 960 cagaagagcc tctccctgtc tccgggtaaa 990 <210> 27 <211> 360 <212> DNA <213> Artificial Sequence <220> <223> Nucleotides encoding variable heavy chain <400> 27 cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60 acctgcactg tctctggtgg ctccatcaaa agtggtagtt actactgggg ctggatccgc 120 cagcccccag ggaaggggct ggagtggatt gggaacatct attatagtgg gagcacctac 180 tacaacccgt ccctcagaag tcgagtcacc atatccgtag acacgtccaa gaaccagttc 240 tccctgaagc tgagttctgt gaccgccgca gacacggcgg tgtactactg cgccagagaa 300 ggatcttacc ccaatcagtt tgatccatgg ggacagggta cattggtcac cgtctcctca 360 <210> 28 <211> 321 <212> DNA <213> Artificial Sequence <220> <223> Nucleotide sequence encoding variable light chain <400> 28 gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60 ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 120 ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180 aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240 gaagattttg cagtttatta ctgtcagcag taccactcct tccctttcac ttttggcgga 300 gggaccaagg ttgagatcaa a 321 <210> 29 <211> 385 <212> PRT <213> Artificial Sequence <220> <223> B7-H4 IgV-huIgG1 <400> 29 Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile 1 5 10 15 Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser 20 25 30 Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile 35 40 45 Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu 50 55 60 Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val 65 70 75 80 His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met 85 90 95 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn 100 105 110 Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr 115 120 125 Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu 130 135 140 Tyr Lys Thr Gly Ala Phe Ser Gly Ser Glu Pro Lys Ser Ser Asp Lys 145 150 155 160 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 165 170 175 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 180 185 190 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 195 200 205 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 210 215 220 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 225 230 235 240 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 245 250 255 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 260 265 270 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 275 280 285 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 290 295 300 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 305 310 315 320 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 325 330 335 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 340 345 350 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 355 360 365 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 370 375 380 Lys 385 <210> 30 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Anti-PD-1 Antibody Heavy Chain <400> 30 Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr 65 70 75 80 Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 445 <210> 31 <211> 218 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> Anti-PD-1 antibody <400> 31 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser 20 25 30 Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 85 90 95 Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 32 <211> 120 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> Anti-PD-1 antibody VH amino acid sequence <400> 32 Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr 65 70 75 80 Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 33 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> Anti-PD-1 antibody VL amino acid sequence <400> 33 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser 20 25 30 Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 85 90 95 Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 34 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Anti-PD-1 antibody VH-CDR1 <400> 34 Asn Tyr Tyr Met Tyr 1 5 <210> 35 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Anti-PD-1 antibody VH-CDR2 <400> 35 Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys 1 5 10 15 Asn <210> 36 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Anti-PD-1 Antibody VH-CDR3 <400> 36 Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr 1 5 10 <210> 37 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Anti-PD-1 Antibody VL-CDR1 <400> 37 Arg Ala Ser Lys Gly Val Ser Thr Ser Gly Tyr Ser Tyr Leu His 1 5 10 15 <210> 38 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Anti-PD-1 Antibody VL-CDR2 <400> 38 Leu Ala Ser Tyr Leu Glu Ser 1 5 <210> 39 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Anti-PD-1 Antibody VL-CDR3 <400> 39 Gln His Ser Arg Asp Leu Pro Leu Thr 1 5 <210> 40 <211> 288 <212> PRT <213> Homo sapiens <400> 40 Met Gln Ile Pro Gln Ala Pro Trp Pro Val Val Trp Ala Val Leu Gln 1 5 10 15 Leu Gly Trp Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp 20 25 30 Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp 35 40 45 Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val 50 55 60 Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala 65 70 75 80 Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg 85 90 95 Val Thr Gln Leu Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg 100 105 110 Ala Arg Arg Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu 115 120 125 Ala Pro Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val 130 135 140 Thr Glu Arg Arg Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro 145 150 155 160 Arg Pro Ala Gly Gln Phe Gln Thr Leu Val Val Gly Val Val Gly Gly 165 170 175 Leu Leu Gly Ser Leu Val Leu Leu Val Trp Val Leu Ala Val Ile Cys 180 185 190 Ser Arg Ala Ala Arg Gly Thr Ile Gly Ala Arg Arg Thr Gly Gln Pro 195 200 205 Leu Lys Glu Asp Pro Ser Ala Val Pro Val Phe Ser Val Asp Tyr Gly 210 215 220 Glu Leu Asp Phe Gln Trp Arg Glu Lys Thr Pro Glu Pro Pro Val Pro 225 230 235 240 Cys Val Pro Glu Gln Thr Glu Tyr Ala Thr Ile Val Phe Pro Ser Gly 245 250 255 Met Gly Thr Ser Ser Pro Ala Arg Arg Gly Ser Ala Asp Gly Pro Arg 260 265 270 Ser Ala Gln Pro Leu Arg Pro Glu Asp Gly His Cys Ser Trp Pro Leu 275 280 285 <210> 41 <211> 290 <212> PRT <213> Homo sapiens <400> 41 Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu 1 5 10 15 Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr 20 25 30 Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu 35 40 45 Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile 50 55 60 Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser 65 70 75 80 Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn 85 90 95 Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr 100 105 110 Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val 115 120 125 Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val 130 135 140 Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr 145 150 155 160 Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser 165 170 175 Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn 180 185 190 Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr 195 200 205 Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu 210 215 220 Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His 225 230 235 240 Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr 245 250 255 Phe Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys 260 265 270 Gly Ile Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu 275 280 285 Glu Thr 290

Claims

1. Use of an anti-B7-H4 antibody or an antigen-binding fragment thereof and an anti-PD-1 antibody or an antigen-binding fragment thereof in the manufacture of a medicament for treating a solid tumor in a human subject, wherein: (i) administering about 0.1 to about 20 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof specifically binds to human B7-H4 and comprises a heavy chain variable region (VH) complementarity determining region (CDR) 1 as shown in SEQ ID NO:5, a VH CDR2 as shown in SEQ ID NO:6, a VH CDR3 as shown in SEQ ID NO:7, a light chain variable region (VL) CDR1 as shown in SEQ ID NO:8, a VL CDR2 as shown in SEQ ID NO:9, and a VLCDR3 as shown in SEQ ID NO:10; and (ii) administering about 200 mg of the anti-PD-1 antibody or its antigen-binding fragment, wherein the anti-PD-1 antibody or its antigen-binding fragment comprises a VH CDR1 as shown in SEQ ID NO:34, a VH CDR2 as shown in SEQ ID NO:35, a VH CDR3 as shown in SEQ ID NO:36, a VL CDR1 as shown in SEQ ID NO:37, a VL CDR2 as shown in SEQ ID NO:38, and a VL CDR3 as shown in SEQ ID NO:

39.

2. Use of (a) a pharmaceutical composition comprising an anti-B7-H4 antibody or an antigen-binding fragment thereof and a pharmaceutically acceptable excipient and (b) a pharmaceutical composition comprising an anti-PD-1 antibody or an antigen-binding fragment thereof and a pharmaceutically acceptable excipient in the manufacture of a medicament for treating a solid tumor in a human subject, wherein: (a) the anti-B7-H4 antibody or antigen-binding fragment thereof specifically binds to human B7-H4 and comprises a VH CDR1 as shown in SEQ ID NO:5, a VH CDR2 as shown in SEQ ID NO:6, a VH CDR3 as shown in SEQ ID NO:7, a VL CDR1 as shown in SEQ ID NO:8, a VL CDR2 as shown in SEQ ID NO:9, and a VL CDR3 as shown in SEQ ID NO:10, At least 95% of the anti-B7-H4 antibodies or antigen-binding fragments thereof in the composition are non-fucosylated, and administering about 0.1 to about 20 mg / kg of the antibody or antigen-binding fragment thereof; and (b) the anti-PD-1 antibody or antigen-binding fragment thereof comprises a VHCDR1 as shown in SEQ ID NO: 34, a VH CDR2 as shown in SEQ ID NO: 35, a VHCDR3 as shown in SEQ ID NO: 36, a VL CDR1 as shown in SEQ ID NO: 37, a VLCDR2 as shown in SEQ ID NO: 38, and a VL CDR3 as shown in SEQ ID NO: 39, and about 200 mg of the anti-PD-1 antibody or antigen-binding fragment is administered.

3. The use of claim 1 or 2, wherein about 20 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

4. The use of claim 1 or 2, wherein about 10 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

5. The use of claim 1 or 2, wherein about 3 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

6. The use of claim 1 or 2, wherein about 1 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

7. The use of claim 1 or 2, wherein about 0.3 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

8. The use of claim 1 or 2, wherein about 0.1 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

9. The use according to claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are administered simultaneously.

10. The use according to claim 9, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are administered on the same day as separate preparations.

11. The use according to claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are administered sequentially.

12. The use according to claim 11, wherein the anti-PD-1 antibody or the antigen-binding fragment thereof is administered after the anti-B7-H4 antibody or the antigen-binding fragment thereof is administered.

13. The use of claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is administered approximately once every three weeks.

14. The use according to claim 1 or 2, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered approximately once every three weeks.

15. The use of claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are each administered approximately once every three weeks.

16. The use of claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is administered intravenously.

17. The use according to claim 1 or 2, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered intravenously.

18. The use of claim 1 or 2, wherein B7-H4 has been detected in the solid tumor using immunohistochemistry (IHC) prior to administration.

19. The use according to claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a VH with an amino acid sequence as shown in SEQ ID NO: 11 and / or a VL with an amino acid sequence as shown in SEQ ID NO:

12.

20. The use of claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment comprises a heavy chain constant region and / or a light chain constant region.

21. The use according to claim 20, wherein the heavy chain constant region is a human immunoglobulin IgG1 heavy chain constant region, and / or wherein the light chain constant region is a human immunoglobulin IgGκ light chain constant region.

22. The use according to claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain constant region with an amino acid sequence as shown in SEQ ID NO: 25 and / or a light chain constant region with an amino acid sequence as shown in SEQ ID NO:

23.

23. The use according to claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO: 21 and / or a light chain having an amino acid sequence as shown in SEQ ID NO:

22.

24. The use according to claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is a human antibody or antigen-binding fragment thereof.

25. The use of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is afucosylated.

26. The use of claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is a full-length antibody.

27. The use of claim 1 or 2, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is an antigen-binding fragment.

28. The use of claim 27, wherein the antigen binding fragment comprises Fab, Fab', F(ab')2, single-chain Fv (scFv), disulfide-linked Fv, V-NAR domain, IgNar, intracellular antibody, IgGΔCH2, mini antibody, F(ab')3, tetravalent antibody, trivalent antibody, bivalent antibody, single domain antibody, Fcab, mAb 2 , (scFv)2 or scFv-Fc.

29. The use of claim 2, wherein fucosylation of the anti-B7-H4 antibody or antigen-binding fragment thereof is not detectable in the composition.

30. The use according to claim 1 or 2, wherein the anti-PD-1 antibody or antigen-binding fragment comprises a VH with an amino acid sequence as shown in SEQ ID NO: 32 and a VL with an amino acid sequence as shown in SEQ ID NO:

33.

31. The use of claim 1 or 2, wherein the anti-PD-1 antibody is pembrolizumab.

32. The use of claim 31 , wherein 200 mg of pembrolizumab is administered.

33. The use of claim 1 or 2, wherein (i) the anti-B7-H4 antibody or antigen-binding fragment thereof specifically binds to human B7-H4 and comprises a VH having an amino acid sequence as shown in SEQ ID NO: 11 and a VL having an amino acid sequence as shown in SEQ ID NO: 12, the anti-B7-H4 antibody or antigen-binding fragment thereof is not detectably fucosylated, and 3, 10 or 20 mg / kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered; and (ii) 200 mg of pembrolizumab is administered; Wherein (i) and (ii) are administered intravenously as separate preparations on the same day.

34. The use of claim 33, wherein the anti-B7-H4 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO: 21 and a light chain having an amino acid sequence as shown in SEQ ID NO:

22.

35. The use of claim 1 or 2, wherein the solid tumor expresses B7-H4.

36. The use of claim 1 or 2, wherein the solid tumor is unresectable, locally advanced or metastatic.

37. The use of claim 1 or 2, wherein the solid tumor is selected from the group consisting of breast cancer, ductal carcinoma, endometrial cancer, ovarian cancer, urothelial carcinoma, non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer and bladder cancer.

38. The use of claim 37, wherein the solid tumor is breast cancer or ovarian cancer.

39. The use according to claim 38, wherein the solid tumor is breast cancer.

40. The use according to claim 39, wherein the breast cancer is advanced breast cancer.

41. The use of claim 38, wherein the breast cancer is triple-negative breast cancer.

42. The use of claim 38, wherein the breast cancer is hormone receptor (HR) positive breast cancer.

43. The use of claim 37, wherein the non-small cell lung cancer is squamous cell carcinoma.

44. The use of claim 1 or 2, wherein the subject has not received prior therapy with a PD-1 / PD-L1 antagonist.

45. The use of claim 1 or 2, wherein the number of immune cells in the tumor is monitored.

46. ​​The use of claim 1 or 2, wherein the number of natural killer (NK) cells, CD4+ cells and / or CD8+ cells in the tumor is monitored.

47. The use of claim 1 or 2, wherein cytokine levels in the subject are monitored.

48. The method of claim 1 or 2, wherein the levels of IL-2, IL-6, IL-10, TNF and / or interferon gamma (IFNγ) are monitored in the subject.

49. Use of (i) an anti-B7-H4 antibody that specifically binds to human B7-H4 and (ii) an anti-PD-1 antibody in the manufacture of a medicament for treating a solid tumor in a human subject, wherein (i) administering about 20 mg / kg of an anti-B7-H4 antibody that specifically binds to human B7-H4 and comprises a VH having an amino acid sequence as shown in SEQ ID NO: 11 and a VL having an amino acid sequence as shown in SEQ ID NO: 12; and (ii) administering about 200 mg of an anti-PD-1 antibody comprising a VH having an amino acid sequence as shown in SEQ ID NO: 32 and a VL having an amino acid sequence as shown in SEQ ID NO: 33, wherein the anti-B7-H4 antibody and the anti-PD-1 antibody are administered intravenously approximately once every three weeks.

50. Use of (a) a pharmaceutical composition comprising an anti-B7-H4 antibody that specifically binds to human B7-H4 and a pharmaceutically acceptable excipient and (b) a pharmaceutical composition comprising an anti-PD-1 antibody or an antigen-binding fragment thereof and a pharmaceutically acceptable excipient in the manufacture of a medicament for treating a solid tumor in a human subject, wherein (a) the anti-B7-H4 antibody that specifically binds to human B7-H4 comprises a VH with an amino acid sequence as shown in SEQ ID NO: 11 and a VL with an amino acid sequence as shown in SEQ ID NO: 12, At least 95% of the anti-B7-H4 antibodies in the composition are afucosylated, and administering about 20 mg / kg of the antibody; and (b) the anti-PD-1 antibody or antigen-binding fragment thereof comprises a VH with an amino acid sequence as shown in SEQ ID NO: 32 and a VL with an amino acid sequence as shown in SEQ ID NO: 33, and about 200 mg of the anti-PD-1 antibody or antigen-binding fragment is administered, and Wherein (a) and (b) are administered intravenously approximately once every three weeks.

51. The use of claim 49 or 50, wherein the anti-B7-H4 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO: 21 and a light chain having an amino acid sequence as shown in SEQ ID NO:

22.

52. The use according to claim 49 or 50, wherein the anti-PD-1 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO: 30 and a light chain having an amino acid sequence as shown in SEQ ID NO:

31.

53. The use of claim 49 or 50, wherein the solid tumor is breast cancer or ovarian cancer.

54. The use of claim 53, wherein the breast cancer is triple negative breast cancer.